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Insights into Neuroblastoma Initiation and Disease Progression Through
integrative Genomics and Epigenomics
Abstract
In this dissertation, we use integrative genomics to shed new insights into the molecular lesions and
mechanisms that drive neuroblastoma. In Part 1, we use imputation and epigenetic profiling in order to
identify the causal germline SNP that drives differential susceptibility to neuroblastoma at the LMO1
oncogene locus. In Part 2, we use whole genome sequencing and Bayesian statistical modeling to
understand the clonal evolution that occurs between diagnosis and relapse.
Part 1: Neuroblastoma is a pediatric malignancy that typically arises in early childhood, and is derived
from the developing sympathetic nervous system. A previous genome-wide association study identified
common polymorphisms at the LMO1 gene locus that are highly associated with neuroblastoma
susceptibility and oncogenic addiction to LMO1 in the tumor cells. Here we investigate the causal DNA
variant at this locus. We show that SNP rs2168101 G>T is the most highly associated variant and resides
in a super-enhancer defined by extensive acetylation of histone H3 lysine 27 within the first intron of
LMO1. The ancestral G allele that is associated with tumor formation resides in a conserved GATA
transcription factor binding motif. We show that the newly evolved protective TATA allele ablates GATA3
binding and enhancer activity, and is associated with decreased total and allele-specific LMO1 expression
in neuroblastoma primary tumors. These findings indicate that a recently evolved polymorphism within a
super-enhancer element in the first intron of LMO1 influences neuroblastoma susceptibility through
differential GATA transcription factor binding and direct modulation of LMO1 expression in cis.
Part 2: The majority of high-risk neuroblastomas initially respond to chemotherapy, but over half of
patients will experience therapy-resistant relapses which are nearly always fatal. The molecular defects
driving relapse and drug resistance are unknown. We performed whole genome sequencing of 23 paired
diagnostic and relapsed neuroblastomas, and corresponding normal lymphocyte DNAs, to define genetic
alterations associated with relapse. Unbiased pathway analysis of the somatic mutations detected in the
relapse tissues identified a strong enrichment in genes associated with RAS-MAPK signaling (18 of 23
patients). These RAS-MAPK mutations were clonally enriched at relapse and exist within clonal or major
subclonal tumor populations. Similar MAPK pathway mutations were detected in 11 of 18 human
neuroblastoma-derived cell lines, and these lesions are predicted to be sensitive to small molecule
inhibition of MEK in vitro and in vivo. In this study of 23 neuroblastoma cases, MAPK pathway mutations
were highly enriched in the relapsed genomes, providing a potential biomarker for new therapeutic
approaches to chemotherapy refractory disease.
Collectively, these studies provide important insights into the genetic and epigenetic factors driving
neuroblastoma, and suggest new opportunities for pathway-targeted therapies.
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ABSTRACT
INSIGHTS INTO NEUROBLASTOMA INITIATION AND DISEASE
PROGRESSION THROUGH INTEGRATIVE GENOMICS AND EPIGENOMICS
Derek A. Oldridge
John M. Maris
Sharon J. Diskin
In this dissertation, we use integrative genomics to shed new insights into the
molecular lesions and mechanisms that drive neuroblastoma. In Part 1, we use imputation and epigenetic profiling in order to identify the causal germline SNP that drives
di↵erential susceptibility to neuroblastoma at the LMO1 oncogene locus. In Part 2,
we use whole genome sequencing and Bayesian statistical modeling to understand the
clonal evolution that occurs between diagnosis and relapse.
Part 1: Neuroblastoma is a pediatric malignancy that typically arises in early
childhood, and is derived from the developing sympathetic nervous system. A previous
genome-wide association study identified common polymorphisms at the LMO1 gene
locus that are highly associated with neuroblastoma susceptibility and oncogenic
addiction to LMO1 in the tumor cells. Here we investigate the causal DNA variant at
this locus. We show that SNP rs2168101 G!T is the most highly associated variant
and resides in a super-enhancer defined by extensive acetylation of histone H3 lysine 27
within the first intron of LMO1. The ancestral G allele that is associated with tumor
formation resides in a conserved GATA transcription factor binding motif. We show
that the newly evolved protective TATA allele ablates GATA3 binding and enhancer
activity, and is associated with decreased total and allele-specific LMO1 expression
in neuroblastoma primary tumors. These findings indicate that a recently evolved
polymorphism within a super-enhancer element in the first intron of LMO1 influences
vi

neuroblastoma susceptibility through di↵erential GATA transcription factor binding
and direct modulation of LMO1 expression in cis.
Part 2: The majority of high-risk neuroblastomas initially respond to chemotherapy,
but over half of patients will experience therapy-resistant relapses which are nearly
always fatal. The molecular defects driving relapse and drug resistance are unknown.
We performed whole genome sequencing of 23 paired diagnostic and relapsed neuroblastomas, and corresponding normal lymphocyte DNAs, to define genetic alterations
associated with relapse. Unbiased pathway analysis of the somatic mutations detected
in the relapse tissues identified a strong enrichment in genes associated with RASMAPK signaling (18 of 23 patients). These RAS-MAPK mutations were clonally
enriched at relapse and exist within clonal or major subclonal tumor populations.
Similar MAPK pathway mutations were detected in 11 of 18 human neuroblastomaderived cell lines, and these lesions are predicted to be sensitive to small molecule
inhibition of MEK in vitro and in vivo. In this study of 23 neuroblastoma cases, MAPK
pathway mutations were highly enriched in the relapsed genomes, providing a potential
biomarker for new therapeutic approaches to chemotherapy refractory disease.
Collectively, these studies provide important insights into the genetic and epigenetic
factors driving neuroblastoma, and suggest new opportunities for pathway-targeted
therapies.
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Chapter 1

An introduction to neuroblastoma
genomics.
1.1

Neuroblastoma at a glance and the promise of
targeted therapies

Neuroblastoma is a neural-crest-derived cancer of the developing sympathetic
nervous system that most commonly arises from the adrenal gland of children under 5
years of age, but can present anywhere along the sympathetic chain[1, 2]. It accounts
for 10% of all pediatric cancer and is responsible for close to 15% of all pediatric cancer
deaths[1, 2]. Although familial neuroblastoma with an autosomal dominant inheritance
pattern occurs in approximately 1-2% of all cases, the majority of neuroblastomas
are sporadic[1, 2]. Moreover, neuroblastoma is recognized as a highly heterogeneous
malignancy that includes multiple clinically and molecularly distinct subclasses[3–
5]. Representing one extreme is stage 4S neuroblastoma, which presents as widely
disseminated disease, but is characterized by the possibility of spontaneous regression
and survival probability of 92%[2, 6]. On another extreme is high-risk neuroblastoma,
which is characterized by MYCN gene amplification, more advanced stage, and/or
older age of onset[7]. The prognosis for high-risk neuroblastoma remains poor with a 5
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year survival probability of approximately 40%, and relapsed high-risk neuroblastoma
is nearly always fatal, with a 5 year overall survival rate of less than 5%[1, 2]. These
poor outcomes persist in spite of aggressive treatment typically consisting of surgery,
radiotherapy, and/or cytotoxic chemotherapy, as well as the recent addition of antiGD2 immunotherapy[8]. Moreover, even when efficacious, such treatments can leave
patients with long-term physical or cognitive impairment[9].
The past two decades have seen the emergence of a generation of cancer therapeutics that directly target the underlying molecular drivers of specific malignancies,
holding great promise to increase treatment efficacy while simultaneously decreasing treatment-related toxicity[10]. The development of trastuzumab for treatment of
HER2-amplified breast cancer[11] and imatinib for BCR-ABL-translocated chronic
myelogenous leukemia[12] are among the earliest, prototypical examples of how identification of molecular lesions has been exploited for therapeutic benefit in specific
cancers. This paradigm, successfully applied in other cancers, provides the rationale
and impetus for characterizing the genome of neuroblastoma: first, to understand the
fundamental molecular basis of this disease, and ultimately to translate this understanding into better treatments. As immune checkpoint blockade and other immune-based
therapies have recently emerged as new and powerful treatment modalities[13, 14],
genomic profiling may take on additional importance in neo-antigen prediction and in
identifying patients who may benefit from the combination of targeted small molecule
therapies and new immunotherapies[15].

2

1.2

Neuroblastoma genetics in the pre-genomics
era

The first insights into the somatic genome of neuroblastoma came from karyotyping
studies, which revealed recurrent broad segmental chromosomal rearrangements—
including 1p deletion, 11q deletion, and 17q gain—that have long been appreciated for
their prognostic relevance[16–20]. The identification of the first bone fide neuroblastoma
oncogene came in the discovery a c-MYC homologue (named N-Myc or MYCN, for
‘N’euroblastoma) that manifested as double minute chromosomes or homogeneously
staining regions of chromosomes—reflecting > 100-fold amplications of the MYCN
oncogene—in a subset of neuroblastoma tumors[21]. It is now appreciated that high
copy MYCN-amplifications occur in approximately 20% of all neuroblastomas and are
associated with significantly worse prognosis[22]. Indeed, MYCN -amplificiation is one
of the primary criteria for determining what constitutes “high-risk” neuroblastoma
clinically[7].
The earliest e↵orts to characterize somatic point mutations in neuroblastoma,
informed as they were by common mutation types that had been observed in other
cancers, were met with relatively little success. For example, while p53 tumor suppressor
mutations are estimated to occur in approximately half of all cancers[23], it was
discovered early on that p53 mutations are very rare in most neuroblastomas[24, 25].
Similar targeted sequencing studies revealed that RAS oncogene mutations, common
in several other cancer types[26, 27], were also quite rare in neuroblastoma[28, 29].
However, such candidate gene sequencing approaches did meet early luck in the
discovery of PHOX2B as a familial neuroblastoma gene[30, 31], which was motivated
by earlier discovery of PHOX2B mutation as a major cause of another disease of the
neural crest: Congenital Central Hypoventilation Syndrome, also known as “Ondine’s
3

Curse”[32]. In aggregate, the genes identified by these early studies had identified key
oncogenic driver mutations for only a small fraction of neuroblastomas, leaving open
the possibility that neuroblastoma drivers might be hidden in some as yet uncharted
region of the genome and that their discovery would need to await the arrival of
technologies that enabled just such an unbiased, genome-wide search.

1.3

Neuroblastoma genetics in the genomics era

The completion of the Human Genome Project[33, 34], and with it the emergence
of microarray and next generation sequencing (NGS) technologies[35] opened new
avenues for understanding neuroblastoma genetics at a genomic scale. An important
breakthrough came in 2008, when an unbiased linkage analysis uncovered germline
mutations in the kinase domain of Anaplastic Lymphoma Kinase (ALK ) as the major
cause of familial neuroblastoma[36]. Concurrently, genome-wide copy number profiling
had identified high copy somatic ALK amplifications in a subset of neuroblastoma
tumors, and subsequent resequencing demonstrated that point mutations in ALK
occur in approximately 10% of all neuroblastomas[36–39]. In a stroke of serendipity,
hyper-active ALK-signaling mediated by EML4-ALK translocations had already been
identified as a common and druggable lesion in Non-Small Cell Lung Cancer, with
an ALK-inhibitor already in active development[40, 41]. Ultimately, these converging
lines of evidence uncovered ALK as an important driver in a substantial fraction
of neuroblastomas, and the translation of this discovery into targeted therapies for
ALK-mutant neuroblastoma remains an exciting and active area of study[42, 43].
As the cost of whole exome sequencing (WES) and whole genome sequencing (WGS)
have continued to decline, an unbiased picture of the landscape of the neuroblastoma
protein coding genome has emerged over the past few years[44–47]. In 2012, our Dutch
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colleagues published a study of 87 neuroblastoma tumors of all stages, which aside from
alterations in MYCN and ALK, identified recurrent structural alterations in ODZ3
(5.7%), PTPRD (5.7%) and CSMD1 (3.4%)—postulated as regulators neuronal growth
cone stabilization—as well as recurrent structural alterations or point mutations in
ATRX (5.7%), TIAM1 (3.4%), and other regulators of the Rac/Rho pathway[44].
Our laboratory leads the neuroblastoma component of the Therapeutically Applicable
Research to Generate E↵ective Treatments (TARGET) pediatric cancer genomics
project, and in 2013 published a whole exome sequencing study of 222 tumors also
showing a relative dearth of somatic coding mutations, with the most frequently
mutated genes in neuroblastoma being ALK (9%), PTPN11 (2.9%), ATRX (2.5%,
and an additional 7.1% had focal deletions), and NRAS (0.83%)[46]. Unfortunately,
the relative lack of recurrent somatic mutations found in these studies raises important
doubts as to whether precision-based medicine targeted to mutations detected in
diagnostic tumors can be readily generalized to the majority of neuroblastomas.
While the idea that common germline variation might contribute to sporadic
neuroblastoma was initially met with skepticism, an ongoing genome wide association
study (GWAS) has definitively established that common variation contributes to
both neuroblastoma tumor initiation and maintenance, implicating many additional
genes in neuroblastoma tumoriogenesis. These include variants in or near the genes of
BARD1 [48], CASC15 [49], LMO1 [50], LIN28B [51], HACE1 [51], TP53 [52], associated
with high-risk neuroblastoma; variants in or near DUSP12, DDX4, and HSD17B12 [53],
associated with low-risk neuroblastoma; and copy number variation resulting in deletion
of the NBPF23 gene[54]. Although many of these genes have been previously implicated
in other cancers and quite plausibly function as neuroblastoma oncogenes or tumor
suppressors, much work remains to be done to better understand the mechanism
for how genetic variation a↵ects neuroblastoma and to understand how these genes
5

function in neuroblastoma pathogenesis more broadly.

1.4

Summary of challenges in the field of neuroblastoma genomics, circa 2012

The previous sections summarize what was understood in the field of neuroblastoma
genomics prior to the start of my Ph.D. training. On the one hand, an exciting period
of discovery had just implicated neuroblastoma-associated common germline variation
near genes previously unknown to a↵ect disease-initation, but the causal mechanisms
remained to be elucidated. On the other hand, the paucity of recurrent somatic coding
mutations in neuroblastoma provided no clear strategy for the development of rational
therapeutics, with the notable exception of ALK -mutated cases. Moreover, essentially
nothing was known about how neuroblastomas tumors evolve over the course of therapy,
nor what molecular lesions underlie the tumors of patients who ultimately relapse and
who remain in dire need of e↵ective treatment strategies. In the following chapters, I
will summarize how my dissertation work has begun to shed light on exactly these
issues.

6

Chapter 2

Non-coding mechanisms of
functional dysregulation in
neuroblastoma
2.1

Introduction to regulatory genetics and epigenetics

Gene expression programs responsible for cellular di↵erentiation and function are
highly dependent on the packaging of chromatin, a macromolecular complex of DNA
and DNA-binding histone proteins[55]. The partitioning of chromatin into functional
domains is largely determined by chemical, “epigenetic” alterations to DNA and
histones that do not a↵ect the underlying nucleic acid sequence, and by DNA-binding
protein complexes that mediate folding of the genome by pulling together distal regions
of DNA polymers into close proximity in three-dimensional space[56]. This folding, in
turn, establishes which genomic regions will be tightly packaged—transcriptionally
inert “heterochromatin”—versus those regions which will be open and accessible to
the transcriptional machinery—transcriptionally active “euchromatin”. This essential
partitioning of a genome into transcriptionally active and inactive domains is thought
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to play fundamental roles in normal cellular development, di↵erentiation, as well as
disease[57], and provides an explanation for how cells with largely the same genetic
code can be molecularly, morphologically, and functionally distinct[56]. Whereas the
Human Genome Project can be understood as providing the first one-dimensional
structure of the human genome, genome science is increasingly focused on solving the
three-dimensional structure of nuclear DNA and finding its functional and pathological
correlates[57–59].
The paucity of recurrent coding mutations in neuroblastoma suggests that noncoding lesions, including DNA mutations and epigenetic changes, may act as drivers
in a substantial subset of neuroblastoma tumors. Indeed, reports of highly recurrent
TERT promoter mutations driving oncogenic telomerase overexpression in melanoma
through the de novo generation of an ETS transcription factor binding site illustrate
the importance of non-coding mechanisms of cellular dysregulation in cancer[60,
61]. Additionally, the release of Encyclopedia Of DNA Elements (ENCODE)[62]
and Roadmap Epigenomics[63] data—encompassing coding and non-coding RNA,
transcription factor binding, and chromatin profiling in a wide variety of normal and
diseased tissues—provides an unprecedented opportunity to investigate how germline
variation and somatic mutations within newly identified non-coding regulatory regions
may impact cancer.
In meta-analyses of all genotype-phenotype associations discovered to date through
GWAS, is has been estimated that almost 90% of all disease- or phenotype-associated
variants may fall within non-coding regions of the genome[64, 65], raising the important
question of how genetic variation is able to a↵ect phenotypes without changing protein
coding sequences. It is now appreciated that many of these non-coding variants
fall within regulatory regions known as enhancers—regulatory regions that bind to
transcription factors and help promote transcription by looping to distal promoters—
8

and that these regulatory variants modulate enhancer activity (and hence targetgene expression) by disrupting or generating de novo transcription factor binding
sites[65]. Although initially identified in other diseases, this paradigm is emerging as
an important determinant of gene pathway dysregulation in cancer[66]. For example,
a causal germline polymorphism impacting predisposition to breast, prostate, and
colon cancer was discovered to a↵ect MYC expression through modulation of TCF
transcription factor binding within an enhancer region upstream of the MYC protooncogene[67, 68]. In some adult cancers where mature GWAS e↵orts have identified
many cancer-association loci, the focus is now turning to functionally validating many
regions in parallel[69, 70].
Uncovering causal variants from GWAS is difficult for many reasons. One challenge
is posed by the high degree of linkage disequilibrium in the human genome, resulting in
strong correlation and statistical indistinguishability between neighboring variants[71].
Additionally, high-resolution chromatin maps are largely incomplete for most tissues,
whereas mapping needs to be performed in the disease-relevant tissue or cell line due
to the highly tissue-specific nature of chromatin structure. However, of all the neuroblastoma susceptibility loci that were been identified to as of 2012, the LMO1 oncogene
was an especially attractive candidate for searching for regulatory variant candidates.
First, in the initial 2011 study implicating the LMO1 locus in neuroblastoma, it was
observed that risk alleles were associated with higher gene expression[50], consistent
with a regulatory phenotype. Second, only neuroblastoma cell lines possessing the risk
allele showed sensitivity to LMO1 knockdown[50], indicating that LMO1 expression
played an allele-dependent role in tumor maintenance in addition to initiation, thereby
suggesting that neuroblastoma cell lines could be useful models in uncovering causal
variants. Finally, the publication of ENCODE data at the end of 2012[62], which
included DNase I hypersensitivity sequencing marking active enhancer regions along
9

with binding profiles of an array of other transcription factors in neuroblastoma cell
lines, provided the perfect opportunity to see if the regulatory architecture of the
LMO1 locus could help identify candidate functional variants. The following section
describes what we found, and is largely copied with minor edits from our recent
publication in Nature, whose full citation is provided here: [72]. Although this study
represents the collaborative e↵orts of many people, my principal contributions included
the conceptualization and execution of the integration of ENCODE-related data that
identified rs2168101 as a causal variant candidate, performing nearly all bioinformatic
analyses excluding genome-wide imputation and super-enhancer analysis, helping
guide the experimental validation e↵orts which included performing reporter assays
and ChIP-PCR experiments myself, as well as writing the majority of the paper and
making nearly all of the figures.

2.2

Oldridge, Wood, et al. Genetic predisposition
to neuroblastoma mediated by a LMO1 superenhancer polymorphism.

Genome-wide association study (GWAS) e↵orts frequently identify highly statistically significant genetic associations within non-coding regulatory regions of the
genome, but the underlying causal DNA sequence variations have only been identified
in a few instances. A neuroblastoma GWAS has identified several disease susceptibility
loci[48–54], with the signal within the LIM domain only 1 (LMO1 ) locus at 11p15[50],
a transcriptional co-regulator containing two zinc finger LIM domains that nucleate
and regulate transcription factor complexes, being most robust. The main members
of the LMO gene family, LMO1-4, are all implicated in cancer including LMO1 and
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LMO2 translocations in T-cell leukemia[73], and we previously provided the first
evidence that LMO1 was a bona fide neuroblastoma oncogene[50]. Here, we sought
to identify the causal polymorphism(s) driving the LMO1 genetic association with
neuroblastoma susceptibility as a basis for understanding neuroblastoma initiation
and addiction mechanisms.
We first performed fine mapping of associated germline SNPs and indels at the
LMO1 gene locus by imputation to the 1000 Genomes Project for our EuropeanAmerican neuroblastoma GWAS[51]. This identified 27 SNPs with minor allele frequency (MAF) > 0.01 and an association P < 1 ⇥ 10

5

(Figure 2.1 and Table 2.1).

We further prioritized associated variants by evolutionary conservation, and by their
regulatory potential inferred through neuroblastoma-specific DNase I hypersensitivity mapping and chromatin immunoprecipitation sequencing (ChIP-seq) from the
ENCODE Consortium (Figure 2.2). These data showed that the most significantly
associated SNP at the LMO1 locus (rs2168101, odds ratio = 0.67, P = 4.14 ⇥ 10

16

)

resides within a highly conserved and active enhancer region inferred by DNase I
sensitivity and p300 binding in the SKNSH neuroblastoma cell line (Figure 2.2).
Notably, we found no rare or common non-synonymous coding variants in LMO1 in
a combined cohort of 482 unique neuroblastoma cases with germline whole-genome
(n = 136), whole-exome (n = 222) and/or targeted DNA sequencing (n = 183) (see
Table 2.2).
Because rs2168101 genotypes were imputed in our analyses (Figure 2.3), we next
directly genotyped this SNP in 146 out of 2,101 European-American cases, and
measured an 86% imputation accuracy. We additionally directly genotyped rs2168101
in two independent cohorts from the UK and Italy, with both showing robust replication
(Table 2.3). We did not observe replication in an independent African-American cohort.
Notably, the protective T allele is common in Europeans (CEU HapMap: 28%) and
11
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Figure 2.1: Imputation GWAS identifies additional neuroblastomaassociatied variants at the LMO1 locus. Manhattan plot for neuroblastoma
GWAS (cases = 2,101; controls = 4,202). The neuroblastoma-associated region falls
within a 40-kilobase (kb) haplotype block (grey box) in Europeans, encompassing
the LMO1 3’-terminus. rs2168101 is the most associated variant and is moderately
correlated (maximum r2 = 0.52) with other variants. The sentinel SNP reported
previously, rs110419, is also highlighted (#).
East Asians (CHB+JPT HapMap: 32%), but is rare or absent in Africans, indicating
recent expansion of the rs2168101 protective allele in non-African human populations
(Figure 2.4). Meta-analysis demonstrated a combined association P = 7.47 ⇥ 10

29

across 8,553 controls and 3,254 cases (Table 2.3).
As causal SNPs driving GWAS associations may disrupt transcription factor binding
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Table 2.1: Germline variants from 1000 Genomes Project associated with
neuroblastoma susceptibility (P < 10 5 ) in European-American cohort
from imputation-based analysis.
Variant ID
Chrom
(rsID)
(hg19)
rs191871553
11
rs11041809
11
rs11041811
11
rs11041812
11
rs11041813
11
rs10839999
11
rs10769885
11
rs4758049
11
rs4758050
11
rs4758051
11
rs10840000
11
rs7933766
11
rs11041816
11
rs4315061
11
rs72474792
11
rs12797723
11
rs2290451
11
rs7952320
11
rs4758317
11
rs11041820
11
rs3750952
11
rs110419
11
rs110420
11
rs204928
11
rs204926
11
rs2168101
11
rs7948497
11

Position
(hg19)
8222464
8231605
8231665
8231684
8235207
8236083
8236262
8238428
8238545
8238639
8240113
8240464
8243798
8247020
8247885
8247984
8248440
8250143
8250811
8251438
8251921
8252853
8253049
8254433
8255106
8255408
8255855

Alleles
(Ref/Alt)†
C/T
A/G
C/T
C/T
T/C
G/A
C/A
A/C
G/C
G/A
G/C
G/A
A/G
T/C
TATAAAA/T
C/T
C/G
G/C
C/A
G/A
G/C
A/G
T/C
A/G
G/A
C/A
C/G

Alt Allele Freq
(Cases)†
0.035 (n=2101)
0.498 (n=2101)
0.492 (n=2101)
0.492 (n=2101)
0.478 (n=2101)
0.480 (n=2101)
0.513 (n=2101)
0.511 (n=2101)
0.511 (n=2101)
0.510 (n=2101)
0.509 (n=2101)
0.511 (n=2101)
0.397 (n=2101)
0.425 (n=2101)
0.524 (n=2101)
0.443 (n=2101)
0.295 (n=2101)
0.408 (n=2101)
0.514 (n=2101)
0.294 (n=2101)
0.408 (n=2101)
0.441 (n=2101)
0.441 (n=2101)
0.444 (n=2101)
0.440 (n=2101)
0.242 (n=2101)
0.479 (n=2101)

Alt Allele Freq
(Controls)†
0.054 (n=4202)
0.440 (n=4202)
0.434 (n=4202)
0.433 (n=4202)
0.420 (n=4202)
0.423 (n=4202)
0.453 (n=4202)
0.452 (n=4202)
0.452 (n=4202)
0.452 (n=4202)
0.450 (n=4202)
0.453 (n=4202)
0.456 (n=4202)
0.490 (n=4202)
0.456 (n=4202)
0.514 (n=4202)
0.255 (n=4202)
0.480 (n=4202)
0.447 (n=4202)
0.253 (n=4202)
0.481 (n=4202)
0.511 (n=4202)
0.511 (n=4202)
0.512 (n=4202)
0.510 (n=4202)
0.313 (n=4202)
0.419 (n=4202)

P -Value
(Additive)‡
7.49 ⇥ 10 06
1.13 ⇥ 10 07
1.28 ⇥ 10 07
1.22 ⇥ 10 07
1.67 ⇥ 10 07
5.06 ⇥ 10 07
3.77 ⇥ 10 08
7.48 ⇥ 10 08
7.34 ⇥ 10 08
1.22 ⇥ 10 07
6.22 ⇥ 10 08
2.09 ⇥ 10 07
8.99 ⇥ 10 10
1.25 ⇥ 10 09
2.04 ⇥ 10 10
2.05 ⇥ 10 10
8.20 ⇥ 10 06
3.03 ⇥ 10 11
5.76 ⇥ 10 10
6.77 ⇥ 10 06
1.89 ⇥ 10 11
3.16 ⇥ 10 10
3.36 ⇥ 10 10
9.85 ⇥ 10 10
1.97 ⇥ 10 11
4.14 ⇥ 10 16
4.05 ⇥ 10 10

Odds Ratio
(Additive)‡
0.64 (0.53-0.78)
0.80 (0.74-0.87)
0.80 (0.74-0.87)
0.80 (0.74-0.87)
0.81 (0.75-0.87)
0.81 (0.75-0.88)
0.80 (0.74-0.87)
0.81 (0.74-0.87)
0.81 (0.74-0.87)
0.81 (0.75-0.87)
0.80 (0.74-0.87)
0.81 (0.75-0.88)
0.77 (0.71-0.84)
0.78 (0.72-0.84)
0.77 (0.71-0.84)
0.77 (0.71-0.84)
1.23 (1.12-1.34)
1.31 (1.21-1.42)
0.78 (0.72-0.84)
1.23 (1.12-1.34)
0.76 (0.70-0.83)
0.78 (0.72-0.84)
0.78 (0.72-0.84)
0.78 (0.72-0.85)
0.76 (0.70-0.82)
0.67 (0.61-0.74)
1.30 (1.20-1.41)

†Forward strand hg19, imputed genotypes from IMPUTE2, frequencies as reported by SNPTEST.
‡SNPTEST, frequentist score test with additive model, adjusted for gender and top 20 MDS components.

at distal enhancers, we sought to identify candidate SNPs disrupting known JASPAR
motifs[74], which revealed that lead candidate SNP rs2168101 resides in a highly
conserved GATA-binding motif (5’-A[G/T]ATAA-3’, mammalian phastCons score =
100%) (Figure 2.2). Examination of a co-crystallographic structure of GATA3 bound
to its cognate binding motif[75] revealed that that arginine 276 (N-terminal zinc finger)
and arginine 330 (C-terminal zinc finger) both make major groove hydrogen-bonding
contacts with the guanines of separate GATA motifs; either is likely to be sterically
hindered by the methyl group of a substituting thymine, providing structural insight
into the preferential binding of GATA3 to the 5’-GATA-3’ DNA sequence rather
13
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Figure 2.2: Integrative ENCODE analysis reveals that rs2168101 is an
LMO1 enhancer SNP. Neuroblastoma-associated variants (P < 1 ⇥ 10 5 ) are
plotted with ENCODE tracks for neuroblastoma the cell line SKNSH. Two SNPs,
rs2168101 and rs7948497, were annotated “enhancer SNPs” based on overlapping
DNase peaks binding p300. The rs2168101 G!T SNP disrupts an evolutionarily
conserved GATA transcription factor (TF) motif (5’-A[G/T]ATAA-3’). SKNSH has a
rs2168101 = G/G genotype that preserves GATA binding, supported by ENCODE
GATA3 ChIP-seq.
than 5’-TATA-3’ (see Figure 2.5). ENCODE transcription factor ChIP-seq confirmed
GATA2 and GATA3 binding at the rs2168101 GATA motif in the neuroblastoma cell
lines SKNSH and SHSY5Y, which are G/G homozygous, thereby preserving the GATA
motif (Figure 2.2). No other associated variant showed this unique combination of
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Table 2.2: Patient clinical characteristics in referenced sequencing datasets.
Clinical Category

Whole Genome Seq
(Blood/Tumor, n = 136)†

Whole Exome Seq
(Blood/Tumor, n = 222)†

LMO1 -Targeted Seq
(Blood, n = 183)

Transcriptome Seq
(Tumor, n = 127)

0 (0%)
219 (100%)
3

32 (24%)
103 (76%)
1

82 (45%)
101 (55%)
0

8 (6%)
119 (94%)
0

0
0
0
0
219
0

(0%)
(0%)
(0%)
(0%)
(100%)
(0%)
3

0 (0%)
0 (0%)
1 (1%)
6 (4%)
105 (78%)
23 (17%)
1

39 (21%)
13 (7%)
18 (10%)
27 (15%)
78 (43%)
8 (4%)
0

0 (0%)
0 (0%)
0 (0%)
6 (5%)
121 (95%)
0 (0%)
0

MYCN
Not Amplified
Amplified
Not Available

143 (67%)
71 (33%)
8

102 (76%)
32 (24%)
2

151 (83%)
30 (17%)
2

95 (75%)
31 (25%)
1

Histology
Favorable
Unfavorable
Not Available

4 (2%)
187 (98%)
31

29 (23%)
96 (77%)
11

95 (54%)
82 (46%)
6

9 (8%)
107 (92%)
11

DNA Index
Hyperdiploid
Diploid
Not Available

117 (54%)
98 (46%)
7

81 (61%)
52 (39%)
3

121 (67%)
59 (33%)
3

67 (53%)
59 (47%)
1

Risk
Low
Intermediate
High
Not Available

0 (0%)
0 (0%)
219 (100%)
3

15 (11%)
14 (10%)
106 (79%)
1

64 (35%)
49 (27%)
69 (38%)
1

0 (0%)
6 (5%)
121 (95%)
0

Age
< 18 mos
18 mos
Not Available
INSS Stage‡
Stage 1
Stage 2A
Stage 2B
Stage 3
Stage 4
Stage 4S
Not Available

†There is an overlap of 59 neuroblastoma patients with both whole exome and whole genome sequencing. Patients
with targeted sequencing are all unique and do not overlap with whole exome or whole genome cases, yielding 482
unique patients with exonic DNA sequencing of LMO1.
‡International Neuroblastoma Staging System (INSS).

Table 2.3: Replication and meta-analysis of rs2168101 association.
SNP
rs2168101

Ref/Alt

Cohort

MAF Cases

MAF Controls

G/T

Eu-Am†
Italian
U.K.
Af-Am†
Combined

0.242 (n=2101)
0.164 (n=420)
0.190 (n=369)
0.0865 (n=364)

0.313 (n=4202)
0.250 (n=751)
0.311 (n=1109)
0.0891 (n=2491)

Add P -value Add Odds Ratio
(T vs. G)
4.14 ⇥ 10 16 0.67 (0.61-0.74)
2.07 ⇥ 10 06 0.61 (0.50-0.75)
5.86 ⇥ 10 10 0.56 (0.47-0.68)
0.20
0.79 (0.56-1.13)
7.47 ⇥ 10 29 0.65 (0.60-0.70)

Het Odds Ratio
(GT vs. GG)
0.69 (0.62-0.77)
0.57 (0.44-0.74)
0.51 (0.39-0.66)
0.96 (0.71-1.30)
0.67 (0.61-0.73)

Hom Odds Ratio
(TT vs. GG)
0.52 (0.42-0.64)
0.40 (0.21-0.75)
0.31 (0.18-0.53)
1.07 (0.38-3.04)
0.49 (0.41-0.59)

MAF = minor allele frequency; Add = additive model; Het = heterozygous; Hom = homozygous; Eu-Am = EuropeanAmerica; Af-Am = African American
†Imputed genotypes and correction for population stratification.
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Figure 2.3: The imputed SNP, rs2168101, is associated with neuroblastoma, and the risk ‘G’ allele is enriched in neuroblastoma cases. Ternary
density plots of genotype probability vectors [P(G/G), P(G/T), P(T/T)] output from
IMPUTE2 for rs2168101 in the European-American cohort. Vertices represent ‘perfect;
confidence calls in which P(genotype) = 1; dotted lines represent decision boundaries
for genotype calling based on most probable genotype. All plots were normalized by the
total number of individuals studied and subjected to 2D Gaussian kernel smoothing.
Left, 2,101 cases (red); centre, 4,202 controls (blue); right, di↵erence between cases
and controls highlights enrichment of G/G genotype (homozygous risk) in cases and of
G/T and T/T genotypes in controls. Validation e↵orts using PCR-based genotyping
in 146 out of 2,101 European-American cases confirmed an 86% concordance with
imputation based on most probable genotypes.
evolutionary conservation, active enhancer localization, and disruption of a transcription
factor binding motif, including the sentinel SNP rs110419 (P = 1.17 ⇥ 10
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) from

our original report[50].
To test for the possibility of multiple statistical signals or enhancers not marked by
conservation or p300 at the LMO1 locus, we repeated association testing conditional
on imputed rs2168101 genotypes and observed no significant variants after multiple test
correction (most significant variant: rs34544683, nominal P = 9.0 ⇥ 10 4 , Bonferroni
P = 1; Figure 2.6a). To test whether the rs2168101 signal can be equally captured by
other variants, we also performed reciprocal association tests for rs2168101 conditioned
on all 27 other SNPs within 1.5 megabases (Mb) of LMO1 passing thresholds MAF
> 0.01 and nominal P < 1 ⇥ 10 5 . Notably, rs2168101 remained significant across all
16
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Figure 2.4: The protective ‘T’ allele of rs2168101 is rare or absent in
African populations. Shown are allele frequencies for populations that were profiled
as part of the 1000 Genomes Project. Comparative genomic analysis of other vertebrate
species indicates that the risk G allele is ancestral, and the low frequency in African
populations implies that the protective T allele is recently evolved in human history. http://browser.1000genomes.org/Homo_sapiens/Variation/Population?
db=core;r=11:8254908-8255908;v=rs2168101;vdb=variation;vf=1736493
conditional tests (worst-case nominal P = 2.6 ⇥ 10 7 , Bonferroni P = 0.002; Figure
2.6b). These results are consistent with a single underlying signal at the LMO1 locus,
and re-affirm that rs2168101 is the single best causal SNP candidate, because its
association with neuroblastoma cannot be accounted for by other variants.
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We next sought to determine whether rs2168101 genotypes were associated with
LMO1 expression by messenger RNA sequencing (mRNA-seq) of 127 primary high-risk
neuroblastoma tumors. Genotyping rs2168101 yielded 102 G/G, 25 G/T and no T/T
tumors (MAF = 9.8%). We observed significantly higher LMO1 expression in G/G
versus G/T genotype tumors (t-test P = 0.028; Figure 2.7a). Notably, the absence
of protective homozygous T/T genotypes in this high-risk neuroblastoma cohort is
consistent with our previous observation that the risk alleles predispose to the high-risk
phenotypic subset[50] (for clinical covariate associations, see Table 2.4). Accordingly,
the rs2168101 G/G genotype is highly associated with decreased neuroblastoma patient
event-free (P = 0.0004) and overall (P = 0.0004) survival compared to G/T and T/T
genotypes together in our European-American cohort (Figure 2.8). Two cell lines with
homozygous T/T or T/- genotypes expressed LMO1 at comparatively lower levels
than cell lines containing the G allele (Figure 2.9a).
GATA transcription factors mediate chromatin looping and facilitate long-range
enhancer-promoter interactions to regulate target gene expression[78]. We therefore
sought to confirm allelic imbalance of LMO1 transcripts (a hallmark of gene regulation
in cis), which could result from di↵erential GATA-binding caused by rs2168101. First,
because the rs2168101 intronic SNP is not detectable by mRNA-seq, we identified
the LMO1 exonic synonymous SNP, rs3750952, which can measure allelic expression
in the heterozygous state. We identified 45 tumors with the necessary rs3750952
= C/G genotype, and then directly genotyped rs2168101 (G/G = 33, G/T = 12,
T/T = 0) in this panel. By mRNA-seq, there was greater allelic imbalance in 12
tumors that were heterozygous for rs2168101 (G/T) than in 33 homozygous tumors
(rs2168101 = G/G; t-test P < 0.0001; Figure 2.7b). We next used targeted sequencing
of nuclear-enriched nascent RNAs in four neuroblastoma cell lines (G/G = 1, G/T =
2, T/T = 1) to provide direct ascertainment of allele-specific expression at rs2168101.
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Table 2.4: Association of rs2168101 with clinical/biological co-variates.
rs2168101 genotypes*

Association Result

Clinical/Biological
Co-variate
Stage‡4
Not Stage 4

GG
GT
530 (62%) 280 (33%)
611 (56%) 400 (37%)

TT
49 (6%)
74 (7%)

MYCN Amplified
MYCN Non-Amplified

183 (55%)
881 (59%)

115 (34%)
525 (35%)

36 (11%)
83 (6%)

0.00297

1.39 (1.12-1.73)

High-Risk
Not High-Risk

523 (63%)
594 (56%)

263 (32%)
398 (37%)

47 (6%)
73 (7%)

0.00174

0.76 (0.65-0.90)

Unfavorable Histology
Favorable Histology

454 (61%)
527 (57%)

237 (32%)
336 (36%)

48 (6%)
62 (7%)

0.14479

0.88 (0.73-1.05)

DNA Index Hyperdiploid
DNA Index Diploid

685 (59%)
324 (57%)

412 (35%)
198 (35%)

71 (6%)
43 (8%)

0.32009

0.91 (0.76-1.09)

Age 18 mos
Age < 18 mos

621 (61%)
529 (57%)

346 (34%)
338 (36%)

55 (5%)
68 (7%)

0.01448

0.82 (0.69-0.96)

P-Value†
Odds Ratio†
0.01198 0.81 (0.69-0.95)

*Reverse strand hg19, imputed genotypes from IMPUTE2, genotype frequencies as reported by SNPTEST.
†SNPTEST, frequentist score test with additive model, adjusted for gender and top 20 MDS components.
‡International Neuroblastoma Staging System (INSS).

In both heterozygous lines, we observed allelic imbalance that significantly favoured
the risk G allele over the protective T allele (Figure 2.7c). Collectively, these results
indicate that the intact GATA motif at rs2168101 results in significantly higher LMO1
expression levels than the TATA coded by the alternative allele. Allelic imbalance of
LMO1 was not driven by somatic DNA alterations (for example, loss of heterozygosity)
that could a↵ect allelic dosage (Figure 2.9b).
Examination of neuroblastoma transcriptome data for 127 primary tumors showed
that GATA2 and GATA3 are overexpressed compared to other members of the
GATA transcription factor family (Figure 2.10a), and that GATA3 is the most highly
expressed. Additionally, protein immunoblotting showed that GATA3 is uniformly
highly expressed in neuroblastoma cell lines, while LMO1 is highly expressed in the G/G
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(SKNSH and SHSY5Y), G/- (KELLY) and G/T (IMR32) cell lines, but only barely
detectable in the BE2C cell line that lacks a G allele at the rs2168101 locus (Figure
2.10b). We therefore performed ChIP-seq using a GATA3 antibody in neuroblastoma
cell lines, and observed robust GATA3 binding at rs2168101 in lines containing the
G allele (SHSY5Y, KELLY, BE2 and NGP) but not in a line containing only a T
allele (BE2C; Figure 2.11a). We then specifically considered GATA3 ChIP-seq reads
overlapping rs2168101, and we observed strong preferential binding to the G allele
in the G/T heterozygous cell lines BE2 (0.97 G-allele fraction from 38 reads, 95%
confidence interval: 0.86-1.00, Binomial test P = 2.8 ⇥ 10

10

) and NGP (1.00 G-allele

fraction from 6 reads, 95% confidence interval: 0.54-1.00, Binomial test P = 0.03;
Figure 2.11b).
Acetylation of histone H3 at lysine 27 (H3K27ac) is a hallmark of active enhancers[79],
and ChIP-seq analysis of SHSY5Y (G/G; not MYCN amplified), KELLY (G/-; MYCN
amplified), BE2 (G/T; MYCN amplified) and NGP (G/T; MYCN amplified) neuroblastoma cells showed extensive H3K27 acetylation in the first intron of LMO1 across
rs2168101, which was not observed in BE2C (T/-; MYCN amplified; Figure 2.12a).
This region is classified as a super-enhancer in G-allele-containing lines SHSY5Y,
KELLY and BE2 based on enhancer clustering and especially high H3K27ac signal,
a pattern also observed for other known oncogenes and tumor suppressor genes in
this disease[80] (Figure 2.12b and Figure 2.13a). No super-enhancer was observed in
BE2C, Jurkat T-ALL cells that also express LMO1[81], or in other non-neuroblastoma
tissues from ENCODE (Figure 2.12b and Figures 2.13b,c). These results are consistent
with recent evidence that disease-associated SNPs frequently a↵ect enhancers that are
specific to disease-relevant cell lines and tumour histology, and control developmental
stage and tissue-specific gene expression[80, 82–86].
We next performed luciferase reporter assays to measure the e↵ect of rs2168101
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alleles on enhancer activity. HEK293T cells transfected with constructs containing the
risk G allele demonstrated 30-300-fold higher normalized luminescence compared to the
T allele (t-test P = 0.002, Figure 2.14a), whereas luciferase activity of the T allele was
not significantly di↵erent from empty vector, indicating that the intact GATA motif
is required for robust enhancer activity. Finally, knockdown of GATA3 in SHSY5Y
and KELLY cells resulted in both decreased LMO1 protein levels and suppression of
cell growth that was rescued by LMO1 overexpression (Figure 2.14b), indicating the
central role of GATA3 in regulating LMO1 expression levels in neuroblastoma.

2.3
2.3.1

Summary and future directions
Clinical significance and avenues for translational research

Taken together, these data demonstrate the underlying molecular mechanism for
a highly robust genetic association to neuroblastoma, mediated by a single common
causal SNP rs2168101 that disrupts a GATA transcription factor binding site within
a tissue-specific super-enhancer element. The risk allele is associated with a greater
prevalence of high risk disease, and is associated with a worse prognosis independent
of MYCN -amplification. Additionally, the rarity or absence of the protective allele
in African populations and its relative depletion in African-Americans may partially
explain the more aggressive clinical course in African-American children[87]. Moreover,
this work further confirms the utility of association studies to define clinically relevant
oncogenic pathways.
Transcriptional factors and co-regulators, such as LMO1, have not traditionally been
considered “druggable” targets, because they are not enzymatic proteins and therefore
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lack a catalytic domain to which small molecule inhibitors can be designed. Thus, it
will be important to see if ongoing e↵orts to map the downstream targets of LMO1—for
example, by profiling and integrating whole transcriptome changes that accompany
induced LMO1 up- or down-regulation with LMO1 ChIP-seq to identify genes which
are directly bound by LMO1-nucleated transcription factor complexes—may uncover
druggable e↵ectors of LMO1 signaling and suggest new therapeutic strategies. These
LMO1 binding studies are already underway, as part of a newly R01-funded e↵ort
to investigate the broader regulatory landscape of LMO1 in neuroblastoma, both
upstream and downstream.
Early reports that BET bromodomain inhibition can be therapeutically exploited
in neuroblastoma in addition to other c-MYC- or MYCN-driven cancers provides
another possible avenue for translational research. Indeed, the dependence of neuroblastoma cells on super-enhancer-mediated LMO1 expression provides another potential
mechanism for the sensitivity of these tumors to inhibitors of the transcriptional
machinery such as CDK7 and BET bromodomain proteins[82, 84]. Moving forward, it
will be interesting to investigate to what extent chromatin modulators may impinge
on the GATA3-LMO1 enhancer and signaling axis, and may therefore provide another
therapeutic avenue.

2.3.2

In vivo models for tumor initiation

The use of in vivo models to validate the e↵ect of causal variants on cancer initiation
has been limited by many technical challenges, including genetic, epigenetic, and
physiological di↵erences between human and possible model organisms; the relatively
short duration of models compared to human tumorigenesis; difficulty in modeling
complex interactions between multiple pathogenic variants; and the relatively low
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penetrance/e↵ect size of GWAS variants[88]. In this context, we have been fortunate
to maintain a very productive collaboration with the laboratory of Thomas Look at
Dana-Farber, where we have developed transgenic zebrafish models of neuroblastoma to
investigate the role of known or candidate neuroblastoma oncogenes in the developing
nervous system[89].
Such a zebrafish model was already successfully designed to investigate how mutated ALK and hyperactive MYCN cooperate to promote tumorigenesis[90], and in
another model, constitutive co-overexpression of LMO1 and MYCN in the developing
zebrafish decreased tumor latency and increased tumor penetrance relative to MYCN
overexpression alone (Zhu et al., submitted). The observation of metastasis in the
LMO1/MYCN co-overexpressing zebrafish (Zhu et al., submitted) but not in MYCN
overexpressing zebrafish controls raises the tantalizing possibility that LMO1 may
play important roles in promoting metastasis in human neuroblastoma as well, which
remains to be confirmed or ruled out by future studies. In addition, our collaborators
are actively working on zebrafish models of LMO1 enhancer knockout, as well as
introduction of the GATA-ablating T allele of rs2168101, and we are hopeful that
these can be used to further validate the results of the present study.

2.3.3

The role of GATA transcription factors in neuroblastoma

GATA3 has attracted interest in neuroblastoma in recent years, both as a direct
positive regulator of Cyclin D1(CCND1)[91] and for inhibiting di↵erentiation and
promoting stemness[92, 93]. The identification here of GATA3 as a positive regulator
of LMO1 signaling elucidates another facet into how both of these genes function as
oncogenes in neuroblastoma. Although our rescue experiments suggest that LMO1
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may be the primary downstream regulator of GATA3-driven cell proliferation in
neuroblastoma with an active LMO1 enhancer, further studies will be necessary to
clarify whether proposed GATA3-mediated e↵ects on cellular di↵erentiation operate
in concert or separately from LMO1 and/or if GATA3 may operate di↵erently in
the absence of a functioning LMO1 enhancer. In this regard, a crucial starting point
will be to perform co-IP to determine if LMO1 and GATA transcription factors
directly interact as part of the same protein complexes—as has been observed in the
context of blood stem/progenitor cells for the better-studied LMO2[94]—and to parse
out their combinatorial relationship in neuroblastoma by comparison of LMO1 and
GATA2/GATA3 binding profiles.
Recently, a gapped k-mer SVM method has been developed to build robust models
of how underlying DNA sequences can predict chromatin features[95, 96]. Important
applications of this method include prediction of which transcription factors (inferred
by their motifs) are active in a specific cell type, and whether such transcription
factors tend to function predominantly as transcriptional activators or transcriptional
repressors. We have now successfully applied this method to our neuroblastoma
H3K27ac ChIP-seq data, which predicted that GATA transcription factors are one of
the strongest transcriptional activators in neuroblastoma (see Figures 2.15 and 2.16).
This preliminary analysis underscores the potential importance of GATA transcription
factors in maintaining neuroblastoma transcriptional programs, likely at a global
genome-wide scale beyond what we have observed at the LMO1 locus, warranting
further study.
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2.3.4

The non-coding genome of neuroblastoma

The data and approach that were used here to identify the causal variant at the
LMO1 locus has helped lay the groundwork for the discovery of other functional
germline variants and somatic driver mutations that a↵ect non-coding regulatory
regions of the genome in neuroblastoma. One method we have begun to explore
for this purpose is deltaSVM[97], an extension of the gapped k-mer SVM method
mentioned above that uses SVM weights to compute a score to predict whether an
input mutation is likely to be activating (positive score), inactivating (negative score),
or neutral (near zero score) when trained on either H3K27ac ChIP-seq or DNase-seq
or ATAC-seq data. As a validation of this method, we used H3K27ac ChIP-seq data
generated from 8 neuroblastoma cell lines to compute deltaSVM scores for the 27 top
associated variants at the LMO1 locus, which predicted the rs2168101 protective T
allele to be strongly inactivating (Table 2.1 and Figure 2.17).
While the gapped k-mer SVM method (and deltaSVM, by extension) has good
sensitivity and specificity, it su↵ers from low positive predictive value due to the
overwhelming predominance of functionally inert DNA in the human genome[95]. One
way in which this problem can be addressed is to restrict the deltaSVM analysis
only to non-coding regions with a high likelihood of being functionally active, such as
open chromatin regions. To this end, we are pursuing ATAC-seq experiments—a new
transposase-based methodology which combines the advantages of DNase-seq (assessing
chromatin accessibiliy) and MNase-seq (assessing nucleosome positioning)[98]—to map
the chromatin architecture of neuroblastoma with higher resolution than is possible
with current H3K27ac ChIP-seq data.
We are also working to integrate other functional data as additional supportive
evidence of functional non-coding genetic variants or mutations, including expression
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data from TARGET. One general approach is to look for expression outliers that are
associated with specific genetic changes, which can indicate a potential regulatory
phenotype. While the low recurrence of non-coding mutations (similar to coding
mutations) in neuroblastoma presents a difficult challenge, we have already identified a
few possible leads, including a TARGET patient with a mutation in the proximal promoter of MALAT1 that is also a MALAT1 expression outlier (Figure 2.18); MALAT1
stands for “metastasis associated lung adenocarcinoma transcript 1” and is a long
non-coding RNA that has already been extensively associated with cancer[99, 100].
A few additional patients also appear to be expression outliers by RNA-seq but are
unfortunately missing paired WGS data (Figure 2.18), and they will therefore require
targeted sequencing to discern whether their outlier status may also be associated with
promoter mutations. We are also working to integrate allelic imbalance to specifically
look for cis-regulatory signatures from RNA-seq data, though in practice this is not
always possible for any given patient or gene because it depends on the presence of
expressed heterozygous SNPs.
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Figure 2.5: Co-crystal structure of GATA3 bound to its cognate 5’AGATAA-3’ DNA binding motif. GATA3 is drawn as a ribbon, illustrating
the N-terminal zinc finger (blue) and C-terminal zinc finger (red) binding to two
separate DNA molecules, which may reflect how GATA3 is able to facilitate longrange chromatin looping[75]. The red box highlights where the C-terminal zinc finger
arginine 330 residue makes contact with the 5’-AGATAA-3’ motif guanine, forming
two hydrogen bonding contacts. An analogous contact occurs with arginine 276 of
the N-terminal zinc finger. Interestingly, GATA3 R276P mutations are a cause of
hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome[76], reinforcing
the importance of this contact for maintaining proper GATA3 function. Image rendered
in PyMOL from Protein Data Bank[77] structure: 4HC9.
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Figure 2.6: Conditional analysis reveals a single neuroblastoma association
signal at the LMO1 locus. a, Imputation-based neuroblastoma association study
conditional on rs2168101. No variants remain significant after conditioning on rs2168101
(most significant variant: rs34544683, nominal P = 9.0 ⇥ 10 4 , Bonferroni P = 1). b,
Reciprocal analysis conditioned on each of 27 SNPs with a nominal P < 1 ⇥ 10 5 . For
rs2168101, the maximum (least significant) P -value across all non-rs2168101 conditional
tests is shown, illustrating the extent to which the rs2168101 signal can be accounted
for by other variants (a similar statistic is plotted for other variants). Notably, rs2168101
remained significant (worst-case nominal P = 2.6 ⇥ 10 7 , Bonferroni P = 0.002) across
all tests. These results are consistent with a single underlying signal at the LMO1
locus, and re-affirm that rs2168101 is the single best causal SNP candidate because
its association with neuroblastoma cannot be accounted for by other single variants.
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Figure 2.7: Allele-specific expression analysis confirms cis-regulatory signature at the LMO1 locus. a, mRNA-seq across 127 primary tumours genotyped
for rs2168101 (G/G = 102, G/T = 25, T = 0) revealed a significant decrease in LMO1
gene expression between G/T and G/G tumours (t-test P = 0.028). RPKM, reads
per kilobase per million reads. b, Using the synonymous exonic SNP, rs3750952, to
measure allelic expression by mRNA-seq revealed significantly more allelic imbalance
in 12 heterozygous neuroblastoma tumours (rs2168101 = G/T) than in 33 homozygous tumours (rs2168101 = G/G) (t-test P = 5.3 ⇥ 10 5 ). c, Allelic expression for
rs2168101 from targeted nascent RNA-seq in four neuroblastoma cell lines. The two
heterozygous cell lines (rs2168101 = G/T) exhibited significantly reduced T-allele
expression compared to the G allele (t-test P = 1.6 ⇥ 10 4 and 1.5 ⇥ 10 2 for NGP and
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Figure 2.8: The protective T allele of rs2168101 is associated with increased
event-free and overall survival in the European-American discovery cohort.
Because genotypes for rs2168101 are imputed within the European-American discovery
cohort, the most likely genotype for each neuroblastoma case was called based on the
maximum of P(G/G), P(G/T) and P(T/T) from IMPUTE2. P -values reflect Cox
proportional hazards regressions adjusted for MYCN amplification status and the first
20 MDS components to adjust for population stratification. a, Kaplan-Meier plot for
event-free survival. Neuroblastoma cases with rs2168101 = G/G versus rs2168101 =
G/T or T/T showed significantly worse event-free survival (P = 0.0004). b, KaplanMeier plot for overall survival. Neuroblastoma cases with rs2168101 = G/G versus
rs2168101 = G/T or T/T showed significantly worse overall survival (P = 0.0004).
Censored data points are shown as black crosses. Number of at risk patients at every
time point for both event-free survival and overall survival are plotted below each
respective Kaplan-Meier plot.
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Figure 2.9: rs2168101 genotype is associated with total and allele-specific
LMO1 expression in neuroblastoma cell lines and primary tumours, and
allele-specific expression di↵erences are not driven by somatic DNA copy
number alterations. a, Neuroblastoma cell line LMO1 mRNA expression as quantified by A↵ymetrix U95Av2 oligonucleotide arrays was significantly higher in cell
lines harbouring homozygous risk alleles (G/G) compared to heterozygous alleles
(G/T) (P = 0.047, Mann-Whitney two-tailed). b, Allele-specific expression measured
by RNA-seq from primary neuroblastoma tumours. Since rs2168101 is an intronic
SNP that is spliced out in mRNA, the synonymous exonic SNP rs3750952 was used as
a surrogate for measuring allele-specific expression in 39 primary tumours which are
heterozygous for rs3750952 (C/G genotype). The DNA allelic fraction for rs3750952
determined by whole exome sequencing is plotted on the x-axis, whereas the RNA
allele fraction for rs3750952 determined by mRNA-seq is plotted on the y-axis. The
solid line indicates where DNA and RNA allele fractions are equal and dotted lines
indicate the boundary where DNA and RNA allele fractions are within 10% of each
other. Tumors that are heterozygous for rs2168101 (G/T genotype, red dots) exhibit
greater RNA allelic imbalance (P = 5.3 ⇥ 10 5 ) than homozygous controls (rs2168101
= G/G genotype, black dots). By contrast, DNA allelic imbalance is no di↵erent
between G/T versus G/G tumours (P = 0.79), indicating that a cis-acting regulatory
mechanism, rather than somatic DNA alterations, drives LMO1 allelic expression
di↵erences.
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Figure 2.10: Expression of LMO1 and GATA-family transcription factors
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shown below individual cell lines.
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identified in BE2, KELLY and SHSY5Y cells, which all contain the G allele of rs2168101,
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Figure 2.14: a, Luciferase reporter assay for LMO1 enhancer region. The risk G allele
preserved enhancer activity (t-test P = 0.002 across n = 4 independent clones, each
with n = 5 technical replicates), whereas the protective T allele was indistinguishable
from empty vector. b, Left, protein blots for GATA3, LMO1 and tubulin in SHSY5Y
cells treated with control (siControl) short interfering RNAs (siRNAs), or with siRNAs
targeting GATA3 (siGATA3-1 and siGATA3-2), at 72 h post-treatment. Right, cell
counts for cell lines SHSY5Y, KELLY, KELLY stably overexpressing control vector
(EV) and KELLY with forced LMO1 overexpression (LMO1-1 and LMO1-2) treated
with siRNAs at 72 h post-transfection. Rescue of suppressed cell growth after GATA3
depletion by forced LMO1 expression was observed at 72 h. Error bars denote ± s.e.m.
*P < 0.05, **P < 0.001 by t-test. n = 3 independent transfections, n = 9 technical
replicates.
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Figure 2.15: GATA transcription factor binding motifs are the sequences
most highly associated with active chromatin regions in Kelly neuroblastoma cell line. These data reflect training gapped k-mer SVM on H3K27ac ChIP-seq
data from the Kelly neuroblastoma cell line. Following SVM training, the top 1000
10-mer sequences with the strongest positive weights were input into MEME for
unbiased motif discovery. Among the top three motifs, the first and third both match
well to GATA transcription factors (5’-AGATAA-3’). The second motif is consistent
with ETS transcription factors (5’-GGAA-3’).
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Figure 2.16: GATA transcription factor binding motifs are universally activating in neuroblastoma cell lines. These data reflect training gapped k-mer SVM
on H3K27ac or H3K4me1 ChIP-seq data from neuroblastoma cell lines as indicated.
Histograms reflect gapped k-mer SVM weights for all 10-mer sequences containing
a 5’-AGATAA-3’ motif or its reverse complement, 5’-TTATCT-3’. In all cell lines
tested, the AGATAA motifs are biased toward higher weights, indicating that they are
strongly associated with H3K4me1 and H3K27ac bound regions and suggesting that
GATA transcription factors are likely to function as strong transcriptional activators
at a genome-wide scale in neuroblastoma.
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DeltaSVM scores across 8 NBL cell lines with H3K27ac ChIP−seq
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Figure 2.17: DeltaSVM trained on H3K27ac ChIP-seq data predicts
that the protective T allele of rs2168101 is transcriptionally inactivating.
DeltaSVM scores are shown by boxplot based on gapped k-mer SVMs trained on
H3K27ac ChIP-seq profiles across 8 neuroblastoma cell lines for 27 candidate causal
variants at the LMO1 locus (Table 2.1). All 27 candidate causal variants are ranked
by their median deltaSVM score across cell lines. The rs2168101 G!T SNP, predicted
to be inactivating (strong negative score), is highlighted in red.
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Figure 2.18: MALAT1 expression outlier associated with proximal promoter mutation. Scatterplot reflects RPKM expression values as inferred by RNAsequencing of TARGET primary tumors for MALAT1 (y axis) versus MYCN (x axis).
Several expression outliers are observed, and the highest MALAT1 expressing TARGET tumor (patient PASPER) contains an insertion in its proximal promoter region
that disrupts a TALE homeobox motif, which could potentially lead to overexpression
of MALAT1 by a removal of a repressive transcriptional regulator. Other expression
outliers are identified, but unfortunately do not have paired WGS data (gray dots) in
order to confirm whether or not they also contain mutations in the MALAT1 proximal
promoter.
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Chapter 3

Clonal evolution in relapsed
neuroblastomas.
3.1

Challenges for studying the relapsed neuroblastoma genome

Patients with high-risk neuroblastoma have a survival rate of less than 50%[1, 101],
despite extensive treatment involving chemotherapy, surgery, radiation therapy and
immunotherapy. In a majority of patients, an initial response to therapy is observed;
however, up to 60% of these patients subsequently relapse with therapy-resistant
tumors with very poor prognosis[7, 102, 103]. Recently, sequencing of the ALK locus
in neuroblastomas at the time of relapse identified 14 activating mutations in 54 cases
(26%)[104], suggesting that the frequency of ALK aberrations is higher in relapsed
neuroblastoma genomes. However, nearly all next generation sequencing studies of
neuroblastoma genetics to date have focused exclusively on primary tumors[44–47], due
to the scarcity of relapsed neuroblastoma tissue both in the USA and worldwide. This
reflects historical clinical thinking that biopsies are not indicated for relapsed neuroblastoma, given the prevalence of non-invasive diagnostic radiographic techniques[105],
as well as the limited potential for a biopsy to change the clinical course given that
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relapsed neuroblastoma is nearly always fatal[1]. Thus, the neuroblastoma research
field has been faced with a long-standing dilemma: the development of new treatments
for relapsed disease has been hindered by the absence of biopsy material, but a biopsy
has not been ethically indicated unless it would possibly benefit the patient and a↵ect
treatment.
Despite the aforementioned rarity of relapse biopsies, our laboratory in collaboration
with the TARGET project and the Children’s Oncology Group (COG) were able to pull
together matched normal blood, primary tumor, and relapsed tumor tissue “trios” from
nine neuroblastoma patients. This enabled us to perform whole genome sequencing in
order to define the germline and somatic lesions that define relapsed disease, and I
took the lead on the data analysis for this project as part of my dissertation work.
While presenting our results at the 2014 Advances in Neuroblastoma Research (ANR)
Research Congress, we connected with colleagues in the Netherlands and France who
had performed similar WGS analysis in six and eight trios, respectively. Our meeting
ultimately led to a very productive collaboration between our three groups[106], which
will be described in greater detail in the following sections.

3.2

Estimating the clonality/sub-clonality of mutations detected by next generation sequencing

In addition to performing more traditional mutation and copy number analyses in
this dataset, I took the lead in a formal clonality analysis of somatic coding mutations
across primary and relapse tumors. This provided an important opportunity to observe
how neuroblastomas evolve molecularly over the course of therapy and to identify
candidate mutations that may provide a selective advantage and ultimately lead to
treatment resistance. The statistical methodologies that form the basis of this analysis
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have only been developed in the past few years[107–109] and more details about these
methodologies can be found in Appendix A. This section will focus on a illustrative
and practical example of how these approaches have aided our understanding of clonal
structure and evolution in neuroblastoma.
A useful metric for quantifying the relative clonality vs subclonality of mutations is
the cancer cell fraction (CCF), which describes the fraction of the cancer cell population
within a sample that harbor of a mutation. Thus, a clonal mutation is one with a CCF
100% (or estimated to be very close to 100%, practically) and a subclonal mutation is
one with a CCF strictly less than 100%. Generally, this CCF quantity will be larger
than the sample fraction of the mutant population, because a non-zero fraction of
normal contaminating cells (containing only wild-type alleles by definition) will dilute
the apparent prevalence of the mutation when counting mutant versus wild-type alleles
from sequencing data. This problem of normal contamination, in addition to overall
tumor ploidy, are the primary reasons why it is difficult to estimate mutation CCF
from NGS data.
In practice, our laboratory has used Sequenza[109] in order to estimate tumor
purity and ploidy from NGS data as a necessary first step, followed by statistical
modeling laid out in Carter et al. and Landau et al. to estimate somatic point mutation
CCF[107, 108]. The results of running Sequenza on the primary and relapse tumors
of neuroblastoma patient “PASGAP” are shown in Figure 3.1. Although the B-allele
frequency and relative coverage signals in the primary tumor data of PASGAP are
diluted by somewhat lower sample purity (estimated purity of 43% in primary, 75%
in relapse), the overall contamination-corrected profiles are largely concordant and
confirm the expected clonal relationship between primary and relapse tumors.
A closer look at the PASGAP primary and relapse tumors reveals complex copy
number alterations on chromosome 17 (see Figure 3.2). What is particularly interesting
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Figure 3.1: Sequenza results for the primary and corresponding relapse
tumors from patient “PASGAP”. Illustrated are genomic profiles of B-allele
frequency of germline heterozygous SNPs (top) and relative sequencing coverage ratio
(bottom) for primary and relapse tumors. Dotted lines illustrate Sequenza absolute
copy number calls, which take into account normal contamination and overall tumor
ploidy. These results illustrate that after taking into account the relatively lower
purity of the primary tumor, copy number profiles are largely consistent between
primary and relapse tumors, confirming their clonal relationship. Relapse-specific copy
number alterations include gain of 6p, loss of 20p, and complex rearrangements across
chromosome 17.
is that there is a region of relapse-specific hemizygous deletion (which is likely clonal,
see Figure 3.2) and loss of heterozygosity that entirely covers the NF1 tumor suppressor,
which also contains a relapse-specific splice site mutation. While these data suggest
that a sub-population of the PASGAP relapse tumor harbors bi-allelic loss of NF1
function, it is unclear whether or not this NF1 mutation is clonal, given that only
10 out of 15 reads in the relapse tumor show the mutation. However, after adjusting
for tumor purity and ploidy, the CCF estimate with maximum posterior probability
was indeed 100% (see Figure 3.3), indicating that this mutation is very likely clonal.
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Thus, through this methodology we were able to say with some statistical confidence
that patient PASGAP underwent clonal, bi-allelic inactivation of the NF1 tumor
suppressor.
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Figure 3.2: Sequenza results for the primary and corresponding relapse
tumors from patient “PASGAP” at chromosome 17. These data are similar
to Figure 3.1, but focus on chromosome 17 in order to better illustrate the complex
rearrangements in this region. Importantly, the sub-region containing the NF1 tumor
suppressor (vertical black line) underwent a relapse-specific hemizygous deletion leading
to loss of heterozygosity. We can infer that the NF1 deletion is clonal or nearly clonal
because the deleted region falls onto a dotted line (see Appendix A for rationale).
Finally, by integrating DNA WGS and RNA-seq data across primary and relapse
tumors of patient PASGAP, we were able to further validate the functional significance
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Figure 3.3: Bayesian model of cancer cell fraction of NF1 splice site mutation in patient “PASGAP”. Shown is the posterior distribution of CCF for the
relapse-specific splice site mutation in PASGAP, after applying the Bayesian methodology of Carter et al. and Landau et al.[107, 108]. The posterior mode of 100% CCF
suggests that this mutation is quite likely clonal or nearly clonal. A 95% credibility
interval in this case is (65.5, 100%). See Appendix A for methodological details.
of these relapse-specific lesions in the NF1 gene. In particular, we observed that the
splice site mutation in PASGAP resulted in 100% expression of the mutant allele along
with increased intron retention only in the relapse tumor, likely causing premature
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truncation of the NF1 protein (see Figure 3.4). Thus, mutation of an NF1 splice donor
site and hemizygous deletion of the wild-type allele likely conspire to yield clonal
bi-allelic inactivation of the NF1 tumor suppressor. This example illustrates one way
in which RAS-MAPK pathway activation can be achieved in relapsed neuroblastomas.
Premature
Stop Codon

Figure 3.4: DNA and RNA sequencing profiles at the splice donor site that
is mutated in the relapse tumor of patient PASGAP. Only wild-type alleles are
observed in the PASGAP primary tumor, thereby maintaining in an intact splice donor
site and normal splicing of NF1. However, in the PASGAP relapse tumor, mutation of
a splice donor site results in intron retention, evidenced by increased intronic pileup
whose specificity is demonstrated by 100% RNA expression of the mutant allele. The
presence of an immediate in-frame stop codon within this intron likely results in a
premature truncation of the NF1 tumor suppressor and corresponding loss of function.
The following section is largely copied with minor edits from our recent publication
in Nature Genetics, whose full citation is provided here: [106]. Although this study
represents the collaborative e↵orts of many people, my principal contributions included
performing all aspects of whole genome sequencing data analysis of the American
TARGET samples up until the time that we ultimately merged our e↵orts with
our Dutch and French colleagues. During our collaboration, I continued to provide
input and direct contributions to the analysis and presentation of our combined next
generation sequencing data, led all aspects of the clonality analysis described in detail
here, as well as contributing to many of the figures and in writing and editing the
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final manuscript.

3.3

Eleveld, Oldridge, Bernard et al. 2015. Relapsed neuroblastomas show frequent RASMAPK pathway mutations.

We sequenced the genomes of 23 triplet samples constituting primary and relapse
neuroblastomas and lymphocytes. Tumors were of all stages and had variable outcome,
with the only eligibility criterion being the availability of high-quality DNA from
the triplet samples. There was a roughly equal distribution of cases among low-,
intermediate-, and high-risk groups[7]. The median time from diagnosis to relapse
was 11.3 months (range of 1-90 months). Twenty-one of the 23 subjects in this study
received chemotherapy before relapse, and 8 also received radiation therapy, according to
internationally accepted treatment protocols (Table 3.1). Thus, all patients underwent
similar chemotherapy regimens, with high-risk patients additionally receiving radiation
therapy and high-dose chemotherapy with stem cell rescue. No patient on this study
received targeted inhibitors to any oncogenic pathway between the time of diagnosis
and relapse. The majority of low-risk cases received chemotherapy because of the site
and/or size of the primary tumor.
We analyzed the sequence data for somatic mutations resulting in amino acid
changes or located in splice-site regions within 3 bp of an exon, as well as for focal
structural aberrations of regions containing five genes or fewer. There was a median of
14 more mutations in the relapsed samples than in the samples at diagnosis (Figures
3.5 and 3.6). On average, 28% of the mutations detected in the primary tumor were also
detected at relapse, showing that the primary and relapsed tumors were of common
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Table 3.1: Clinical characteristics of the relapse patient cohort.
Patient ID
FR NB1178
FR NB1269
FR NB1382
NL N774
US PATNKP
US PASGAP
NL N790
US PASHFA
FR NB804
NL N607
US PARHAM
US PATYIL
NL N571
US PASNPG
US PARBAJ
US PAUDDK
FR NB1224
FR NB0175
FR NB308
NL N041
US PAPVEB
NL N789
FR NB399

Risk Group Stage
High
4
High
4
High
4
High
4
High
4
High
4
High
3
High
3
Intermediate
4
Intermediate
4
Intermediate
4
Intermediate
4
Intermediate
3
Intermediate
3
Intermediate
3
Intermediate
3
Low
2
Low
2
Low
2
Low
2
Low
2
Low
1
Low
4s

MYCN
Non-amplified
Amplified
Amplified
Non-amplified
Non-amplified
Non-amplified
Amplified
Amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified
Non-amplified

Sex
M
M
M
F
M
M
F
F
F
F
F
F
M
F
M
M
M
M
F
F
M
F
M

Time in Months
Dx Rel Last Status
30 21
24
Dead
14
9
11
Dead
4
50
64
Dead
83
6
10
Dead
113 20
40
Alive
44 42
51
Dead
42 63 110
Dead
13
7
11
Dead
2
26
56
Alive
3
7
84
Alive
11
1
81
Dead
11
8
16
Dead
49 12
16
Dead
10 10
63
Alive
1
10
88
Alive
12 11
38
Alive
15
8
18
Alive
98 90 103
Dead
2
21
91
Alive
109 72
92
Dead
57
9
40
Dead
124 78 168
Alive
0
7
134
Dead

Treatment, Dx
Rad Chem
Y
Y
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
Y
Y
Y
N
Y
N
Y
N
Y
N
Y
N
Y
N
Y
N
Y
N
N
N
Y
Y
Y
N
N
Y
Y
N
Y

! Rel
Surg
Y
Y
Y
Y
Y
Y
Y
Y†
Y
N
N
Y
Y
Y
Y
Y†
N
Y
N
Y
N
Y
N

Dx Location
Rel Location
Retroperitoneum
Liver
Retroperitoneum
Retroperitoneum
Abdomen
Abdomen
Adrenal gland
Abdomen
Retroperitoneum
Pelvis
Adrenal gland
Soft tissue, skull
Adrenal gland
Liver
Adrenal gland
Abdomen
Subcutaneous nodule
Orbita
Liver
Orbita
Pelvis
Pelvis
Abdomen
Pararenal
Adrenal gland
Abdomen
Retroperitoneum
Paraspinal
Retroperitoneum
Abdomen
Pelvis
Pelvis
Mediastinum
Mediastinum
Retroperitoneum
Retroperitoneum
Abdomen
Abdomen
Abdomen
Abdomen
Adrenal gland
Bone marrow
Adrenal gland
Lymph node
Subcutaneous nodule
Liver

Dx = diagnosis; Rel = relapse; Rad = radiation; Chem = chemotherapy; Surg = surgery
†Biopsy only

descent. To gain more insight into the clonal architecture, we estimated the cancer
cell fraction (CCF) of all somatic mutations using a customized reimplementation
of a previously described Bayesian approach[107], which infers CCF from mutant
allele fractions determined by sequencing and accounts for normal contamination and
locus-specific copy number. This analysis yielded a median CCF of 61% for mutations
detected in the primary tumor but lost in the relapse tumor, in comparison to a median
CCF of 90% for primary tumor mutations shared with the relapse tumor (Figure
3.7a), a pattern that is consistent with subclonal outgrowth of the relapsed tumor.
Furthermore, we estimated a median CCF of 83% for all relapse tumor mutations in
comparison to a median CCF of 75% for all primary tumor mutations, indicating clonal
enrichment of a subset of mutations at relapse (Figure 3.7b). Comparison of genes
a↵ected by smaller structural events and chromosomal copy number alterations in
primary and paired relapse tumors showed similar results, with a subset of aberrations
shared but many detected only in the primary or relapse tumor (Figure 3.8).
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Bi-allelic NF1 inactivation
(relapse-specific)

PASGAP Primary Tumor

PASGAP Relapse Tumor

Figure 3.5: Circos plots showing structural alterations and somatic mutations in the primary and corresponding relapse tumors from PASGAP. The
inner ring represents copy number alterations (red, gain; green, loss) identified on
the basis of coverage of the tumor and lymphocyte genomes. The lines traversing the
ring indicate inter- and intrachromosomal rearrangements identified by discordant
mate pairs from paired-end reads. Aberrations are colored according to their presence
(gray, only detected in the primary tumor; black, detected in the primary and relapse
tumors; blue, only detected in the relapse tumor; red, events predicted to activate
RAS-MAPK signaling). PASGAP exhibits bi-allelic inactivation of NF1 that is only
observed at relapse.
Enrichment of mutations that activate RAS-MAPK signaling
Unbiased pathway analysis[110] using whole-genome sequencing data from the
relapse samples on a per-patient basis identified a strong enrichment (P = 6.1 ⇥ 10 7 )
for mutations in genes associated with RAS-mitogen-activated protein kinase (MAPK)
signaling. We next filtered the identified mutated genes against the Cancer Gene
Census[111] and subsequently focused on hotspot regions by selecting mutations
annotated in the Catalogue of Somatic Mutations in Cancer (COSMIC) to identify
events that are well annotated to activate this pathway. Fifteen of 23 relapse samples

49

Single Nucleotide Variants (SNVs)
Somatic Mutations

250
200

Shared

150

Unique primary
Unique relapse

100
50

N

B

1
N 17
B 8
1
N 26
B 9
13
8
N 2
PA 77
T 4
PA N
S KP
G
A
N P
7
PA 9
S 0
H
N FA
B
80
N 4
PA 60
R 7
H
PA AM
TY
I
PA N5 L
7
S 1
PA NP
G
PA RB
A
U J
D
N D
B K
1
N 22
B 4
01
N 75
B
30
8
N
PA 0
4
P 1
V
E
N B
78
N
B 9
39
9

0

Figure 3.6: Count of nonsynonymous mutations identified by wholegenome sequencing in 23 primary tumors and their corresponding relapse
tumors. Mutations identified in both primary and relapse tumors are shown in gray,
whereas mutations unique to the primary or relapse tumor are shown in beige and
blue, respectively. On average, more mutations were observed at relapse, indicating
clonal evolution.
contained somatic mutations that met these criteria. In addition, three relapse samples
showed structural alterations involving these RAS-MAPK pathway genes; thus, we
detected aberrations in this pathway in 18 of 23 relapse samples (78%), and all
alterations were consistent with pathway activation (Table 3.2). Eleven mutations
activating RAS-MAPK signaling that were present in primary tumors were all preserved
in the corresponding relapse tumors. Seven mutations were not detectable in the
primary tumor at the sequencing depth achieved, and we therefore employed ultradeep sequencing to determine whether these mutations were present in fractions under
the whole-genome sequencing detection limit. The ALK mutation in N607 was found
in the primary tumor, whereas the other mutations were undetectable. We assayed
structural aberrations using PCR-based methods. Only the ALK rearrangement in
N790 was shown to be present at low frequency in the primary tumor.
ALK aberrations occurred in ten relapse tumors and were also detected by wholegenome sequencing in seven of the corresponding primary tumors. All detected single50
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Figure 3.7: Relapse tumors undergo clonal evolution over the course of
treatment. The posterior probability distribution of cancer cell fraction (CCF) was
estimated for all somatic coding SNVs by the method of Carter et al.[107] assuming a
somatic multiplicity of one. The expected value of CCF for each SNV, E[CCF], was
then computed under its respective posterior distribution, and the empirical density
of E[CCF] was computed across all somatic coding SNVs and patients and visualized
in the above plots. (a) Comparison of primary tumor mutations that are inherited by
their corresponding relapse tumor versus those that are lost. (b) Comparison of all
primary tumor mutations versus all relapse mutations. The enrichment of high-CCF
mutations at relapse and the loss of low-CCF mutations detected in the primary tumor
are consistent with subclone outgrowth and clonal enrichment of a subset of mutations
at relapse.
nucleotide variants (SNVs) have been proven to constitutively activate this receptor
tyrosine kinase known to activate RAS-MAPK signaling[112]. Furthermore, one relapse
sample showed a de novo amplification giving rise to a PPM1G-ALK fusion gene,
which activated the RAS-MAPK pathway when expressed in neuroblastoma cell lines.
Two tumors showed relapse-specific inactivation of the NF1 tumor-suppressor
gene, through homozygous deletion in one case and heterozygous deletion combined
with a splice-site mutation in the other. NF1 inactivation has been reported in
neuroblastoma and confers activation of RAS-MAPK signaling and resistance to
retinoic acid[113]. One pair of primary and relapse tumors showed a heterozygous
mutation in PTPN11. Mutations in PTPN11 activate RAS-MAPK signaling, and the
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Figure 3.8: Relative coverage plots displaying the structural alterations in
primary and relapse tumors. Coverage was calculated for 1-Mb bins along the
genome and normalized to the coverage in patient lymphocyte DNA. Color intensity
reflects the magnitude of the gain or loss (blue, loss; red, gain) in the associated
chromosomal location. Focal RAS-MAPK-pathway-activating structural alterations
are labeled with arrows. P = primary; R = relapse
identified mutation encoding a p.Ala72Thr substitution has been reported in leukemia
and neuroblastoma[114].
One relapse tumor showed a tandem duplication in the BRAF gene that was not
detected in the primary tumor. This rearrangement leads to expression of a BRAF
transcript that encodes an elongated protein with two kinase domains. Expression
of this BRAF gene with a tandem duplication in a neuroblastoma cell line induced
activation of the RAS-MAPK pathway. Taken together, the somatic mutations detected
in this case series shown to activate the RAS-MAPK pathway were mutually exclusive,
with no case having two somatic events known to hyperactivate this growth-promoting
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Table 3.2: RAS-MAPK pathway mutations in relapsed neuroblastomas.
Patient ID
FR NB1178
FR NB1269
FR NB1382
NL N774
US PATNKP
US PASGAP
NL N790
US PASHFA
FR NB804
NL N607
US PARHAM
US PATYIL
NL N571
US PASNPG
US PARBAJ
US PAUDDK
FR NB1224
FR NB0175
FR NB308
NL N041
US PAPVEB
NL N789
FR NB399

Gene

Genomic aberrations in RAS-MAPK pathway in relapse tumors
Genomic event
Event type COSMIC ID

In primary†

ALK
ALK
PTPN11
FGFR1
NF1
ALK

Somatic mutation (L1196M)
Somatic mutation (Y1278S)
Somatic mutation (A72T)
Somatic mutation (N546K)
Somatic Mutation (Splice Donor) + Hemizygous Deletion
Amplification and fusion

Activating
Activating
Activating
Activating
Inactivating
Activating

99137
28058
13014
19176

Yes
No
Yes
Yes
No
No

ALK
ALK
NRAS
NF1
ALK
HRAS

Somatic mutation (F1174L)
Somatic mutation (R1275Q)
Somatic mutation (Q61K)
Homozygous deletion
Somatic mutation (F1174I)
Somatic mutation (Q61K)

Activating
Activating
Activating
Inactivating
Activating
Activating

28055
28056
580

No
Yes
Yes
No
Yes
No

ALK
ALK
ALK
BRAF
KRAS

Somatic mutation (R1275Q)
Somatic mutation (Y1278S)
Somatic mutation (F1174L)
Tandem duplication catalytic domain
Somatic mutation (G12D)

Activating
Activating
Activating
Activating
Activating

28056
28058
28061
521

Yes
Yes
Yes
No
Yes

ALK

Somatic mutation (R1275Q)

Activating

28056

Yes

28491
496

†Detected in primary tumor by whole genome sequencing analysis

pathway.
We hypothesized that mutations activating RAS-MAPK signaling exhibit relapsespecific enrichment due to treatment. We therefore performed a clonality analysis,
comparing CCF estimates for RAS-MAPK mutations in paired primary (CCFp ) and
relapse (CCFr ) tumors (Figure 3.9). RAS-MAPK mutations were almost universally
present within major subclonal populations at relapse, as indicated by CCFr > 0.5
with probability > 90% under the posterior distribution for 14 of 15 relapse tumors.
In 7 of 15 tumor pairs, there was strong evidence of relapse-specific enrichment of
RAS-MAPK mutations—including mutations in ALK (4 pairs), HRAS (1 pair), KRAS
(1 pair) and NF1 (1 pair)—based on a criterion of CCFr > CCFp with probability
> 90% for each pair. By contrast, the probability that CCFr > CCFp fell within
20-80% bounds for the remaining eight pairs, indicating that RAS-MAPK mutations
that were already present in the primary tumor were retained at relapse. Collectively,
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these results support RAS-MAPK mutations as somatic drivers that undergo positive
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selection over the course of neuroblastoma treatment.

Figure 3.9: RAS-MAPK pathway mutations reside within major relapsed
neuroblastoma subclones. Each of the 15 panels represents a primary-relapse pair
with a corresponding RAS-MAPK pathway mutation. Posterior distributions of CCF
were computed by the method of Carter and colleagues[107] and are represented by
violin plots, with black dots positioned at the distribution medians. Four primaryrelapse pairs (NB1382, PASGAP, N607 and PARBAJ) possess relapse-specific RASMAPK pathway mutations that are undetectable in the corresponding primary tumors
by whole-genome sequencing. Three additional pairs (NB1224, NB308 and PAPVEB)
also show evidence of relapse-specific enrichment of RAS-MAPK mutations based
on the criterion that the probability of CCFr > CCFp was > 90% for each pair.
CCF estimates for ALK mutations in NB308 reflect p.Phe1174Leu (c.352C!A)
and p.Phe1174Leu (c.352C!G) substitutions in the primary and relapse samples,
respectively, as previously described[104].
Chromosomal aberrations
Three relapse samples showed homozygous deletions in the CDKN2A locus, encoding the tumor-suppressor proteins p14ARF and p16, whereas both alleles of CDKN2A
were present in the corresponding primary tumors. CDKN2A deletions were previously
reported as frequent events in neuroblastoma relapse[115]. We detected other relapsespecific segmental chromosome defects, including loss of 6q (five cases) and loss of 17p
(three cases). Furthermore, we detected relapse-specific aberrations that are frequently
detected in primary neuroblastoma and are associated with poor prognosis, including
loss of chromosomes 1p (one case) and 11q (three cases) (Figure 3.8)[18, 20].
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RAS-MAPK pathway mutations and sensitivity to MEK inhibition
To determine whether neuroblastoma cell lines contain RAS-MAPK mutations, we
analyzed whole-genome sequencing data from a series of human-derived neuroblastoma
cell lines for mutations in ALK, NRAS, HRAS, KRAS, BRAF, PTPN11 and NF1.
Eleven of the 18 cell lines showed such mutations.
We tested our cell line panel for sensitivity to the MEK inhibitors trametinib,
cobimetinib and binimetinib, to determine the relationship between mutation status
and drug sensitivity. The data showed clustering of the cell lines into four groups with
increasing sensitivity to MEK inhibition: (i) lines without RAS-MAPK mutations;
(ii) lines with ALK mutations; (iii) lines with NF1 mutations; and (iv) lines with
RAS gene or BRAF mutations. In the cell lines with mutated RAS genes or BRAF,
MEK inhibitor treatment caused almost complete cell cycle arrest at low nanomolar
concentrations, whereas in the NF1 - and ALK -mutated lines the e↵ect on cell cycle
inhibition was less robust (data not shown). When the sensitivity of the cell lines was
expressed as the concentration at which cell growth was inhibited by 50% (GI50 ), there
were significant di↵erences between cell lines with and without RAS-MAPK mutations
(Figure 3.10). GI50 values for the three di↵erent compounds were highly correlated
in the cell line panel, suggesting an on-target e↵ect (r2 = 0.49-0.79; P < 0.01). A
relationship between mutation status and sensitivity to MEK inhibition was also
observed in an independent published data set[116].
To validate that ALK and RAS gene mutations directly activate the RAS-MAPK
pathway in neuroblastoma cells, we induced the expression of an ALK Phe1174Leu
and an NRAS Gln61Lys mutant in two cell lines that did not harbor RAS-MAPK
mutations. Expression of either mutated protein caused activation of the pathway. We
have shown previously that knockdown of NF1 causes hyperactivated RAS-MAPK
signaling in neuroblastoma cell lines[113].
55

b

Binimetinib
***

***

0
-1
-2
-3

p=0.0023

-2

p=0.0135

LK
m
ut
at
ed

A

on
N

on
N

F1

ut
at
ed

m

A

LK

F1
N

F
A
A
S/
R
R

ut
at
ed

LK

m

A

-1

-3

N

on

F1
N

A

F

-4

0

N

-2

1

*

1

F

p=0.0039

2

A

-1

*

***

log10(GI50) ( M)

0

A
S/
R

***

A
S/
R

1

log10(GI50) ( M)

*

2

R

Cobimetinib

***

**

log10(GI50) ( M)

c

Trametinib

R

a

Figure 3.10: Sensitivity of neuroblastoma in vitro cell line models to MEK
inhibition therapy. (a-c) GI50 values for a panel of neuroblastoma cell lines treated
with binimetinib (a), trametinib (b) and cobimetinib (c). Cell lines are grouped
according to mutation status. Red bars represent the mean GI50 value for each group.
P -values were derived from Kruskal-Wallis tests. Student’s t-tests were performed
to determine di↵erences between non-mutated and mutated groups: *P < 0.05,
**P < 0.01, ***P < 0.001.
We next treated various human neuroblastoma-derived cell line xenograft models,
representing the four groups described above, with the MEK inhibitor binimetinib.
SK-N-AS xenografts, which harbor an NRAS mutation encoding p.Gln61Lys, showed
inhibition of tumor growth and increased survival when treated with binimetinib, in a
dose-dependent fashion (Figure 3.11). NBL-S xenografts have an inactivating mutation
in one allele of NF1 and an almost complete absence of NF1 protein expression; these
xenografts also showed inhibition of growth with treatment. Conversely, treatment
of Kelly and IMR-5 xenografts had no e↵ect on tumor growth. IMR-5 cells do not
have RAS-MAPK pathway mutations detectable by whole-exome sequencing (data
not shown), whereas Kelly cells harbor an ALK mutation encoding a p.Phe1174Leu
substitution.
We then determined whether inhibition of cell growth corresponds with inhibition
of the RAS-MAPK pathway in the cell lines that were used for the mouse xenograft
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Figure 3.11: Sensitivity of neuroblastoma cell line-derived xenograft models to MEK inhibition therapy. Human neuroblastoma-derived SK-N-AS, NBL-S,
Kelly and IMR-5 xenografts were treated with binimetinib (3 mg/kg or 30 mg/kg)
or vehicle by oral gavage twice daily. Each cohort consisted of ten mice, and tumor
volumes (cm3 ) and percent survival are shown. Error bars denote ± s.e.m.; significance
is denoted: *P < 0.05.
experiments. We treated the cell lines with increasing concentrations of binimetinib in
vitro for 24 h and screened for ERK phosphorylation. The three lines with RAS-MAPK
mutations showed phosphorylation of ERK under untreated conditions, reaffirming
that these mutations indeed lead to activation of the RAS-MAPK pathway. Upon
exposure to binimetinib, SK-N-AS and NBL-S cells showed a dose-dependent decrease
in the levels of phosphorylated ERK, whereas Kelly cells showed no significant change.
These data suggest that the minimal e↵ect of MEK inhibition in vitro and the absence
of an e↵ect in vivo for the Kelly cell line may be due, at least in part, to continued
ERK phosphorylation. To confirm that the response we observed in vivo was also
due to target inhibition, we analyzed ERK phosphorylation in the xenografts that
responded to treatment and demonstrated a dose-dependent decrease in the levels of
phosphorylated ERK.
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3.4
3.4.1

Summary and future directions
Clinical significance and the need for relapse biopsies

In this study, we characterized the genomes of 23 relapsed neuroblastomas and
compared each to the genome of the corresponding primary tumor. We show that the
relapsed tumors generally contain more mutations and structural aberrations and that
clonal selection takes place between the primary tumor and the relapse tumor. We
found that 18 of 23 relapse tumors harbored mutations predicted to hyperactivate
the RAS-MAPK signaling pathway and that cell lines containing similar mutations
show sensitivity to inhibition of MEK, a downstream node in the canonical growthpromoting pathway. These results provide a strong rationale for recommending biopsy
and genomic characterization of relapsed neuroblastoma tumors and for prioritizing the
clinical testing of MEK inhibition strategies in the treatment of relapsed neuroblastoma.
Because of the sensitivity and specificity of modern imaging modalities, the diagnosis
of neuroblastoma relapse rarely requires a tumor biopsy. In addition, until recently,
there has been no realistic potential for therapeutic benefit based on biopsy results,
and therefore very few relapse neuroblastoma samples are available for study. Here
we collected high-quality material from 23 primary-relapse tumor pairs across the
spectrum of neuroblastoma phenotypes, including those assigned to high-, intermediateand low-risk groups[7]. The only inclusion criterion for this study was the availability
of matched samples, but some cases may have been biopsied owing to an unusual
clinical course. Indeed, there were a fairly high number of intermediate- and low-risk
tumors that normally do not show frequent relapse[7]. However, the frequency of
RAS-MAPK mutations did not di↵er among the groups, so it is unlikely that the
over-representation analysis is influenced by this bias.
The high frequency of RAS-MAPK pathway mutations at diagnosis in this cohort
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was unexpected, as such high frequencies were not reported in whole-genome sequencing
series of primary tumors[44–47]. It is possible that the presence of these lesions in
a diagnostic sample is a biomarker of a more aggressive clinical course and a higher
likelihood of relapse. These findings need to be validated in a prospective patient
cohort.
We detected several recurrent structural aberrations at the time of relapse. Partial
loss of chromosome 6q was observed in five relapse samples, and homozygous deletion
of CDKN2A was found in three relapse samples. Both events are infrequent in primary
neuroblastoma and present interesting targets for further research. Furthermore,
neuroblastoma-associated aberrations such as loss of 1p and 11q were observed in the
relapse tumor and not in the primary tumor, indicating that these events might not be
tumor initiating but rather are crucial steps in neuroblastoma tumor evolution[117].
Events a↵ecting RAS-MAPK signaling were detected in 18 of 23 relapse samples.
In four cases, we identified structural variants, highlighting the benefit of whole-genome
sequencing for detection of the full spectrum of genetic alterations. In 7 of these 18
cases, the mutations were observed only in the relapse tumor, which indicates that
analysis of primary tumor samples is not sufficient to guide the choice of treatment
for neuroblastoma relapses. These findings are in line with the de novo occurrence of
ALK mutations reported previously[104].
The observation that several RAS-MAPK mutations were present in the relapse
tumor but not in the corresponding primary tumor favors a model where subclones
with secondary driver mutations expand over time, possibly under the selective pressure
of chemotherapy, as was recently described for chronic lymphocytic leukemia[108].
Whether these mutations occurred between diagnosis and relapse, were present at
levels below detection limits or were undetectable owing to spatial heterogeneity in
the primary tumor remains to be determined.
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It has been firmly established that mutations in the RAS-MAPK pathway can
occur as resistance mechanisms against treatment with targeted kinase inhibitors[118];
however, no targeted inhibitors were used in the treatment of our patient cohort.
Mutations in the RAS-MAPK pathway may also be associated with resistance to
conventional cytotoxic therapies in neuroblastoma, but more research is needed to
establish the molecular basis of this phenotype.
The ALK gene was mutated in ten relapse samples, and it is known that the
most frequent ALK mutations in neuroblastoma activate the RAS-MAPK signaling
pathway[39]. The results of our xenograft therapeutic studies indicate that single-agent
treatment with a MEK inhibitor might not be e↵ective in ALK -mutated tumors.
However, the finding that ALK-mutated cell lines consistently showed some sensitivity
to MEK inhibition in vitro suggests that activated RAS-MAPK signaling does have a
role in ALK -mutated neuroblastoma and warrants further investigation on the use of
MEK inhibitors in combination therapies. ALK inhibitors have proven to be e↵ective
in the treatment of ALK -mutated tumors[43], but some mutations are associated
with resistance to currently available ALK inhibitors[112]. Therefore, combined MEK
and ALK inhibition might improve response in tumors containing such mutations.
Combination of these inhibitors with ones targeted against other pathways that are
activated in ALK -mutated neuroblastoma, such as phosphoinositide 3-kinase (PI3K)
and mTOR[119, 120] signaling, might also improve therapeutic efficacy.
We also detect mutations in NF1, BRAF, PTPN11, FGFR1 and the three RAS
genes, and all lesions in the RAS-MAPK pathway were mutually exclusive. Cell lines
with RAS-MAPK mutations show moderate to high sensitivity to MEK inhibitors,
and treatment with the inhibitor binimetinib of SK-N-AS xenografts, which contain an
NRAS mutation, as well as NBL-S cells, which have loss of NF1, results in significant
therapeutic efficacy. These findings suggest that MEK inhibition might be of clinical
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benefit in the treatment of neuroblastoma relapses containing RAS-MAPK mutations.

3.4.2

NEPENTHE: a phase 1b/2 clinical trial for relapsed
neuroblastoma

Our observation of RAS-MAPK pathway-activating mutations in relapsed neuroblastomas has provided part of the rationale for NEPENTHE, a soon to open pediatric
cancer phase 1b/2 clinical trial that will match genomic aberrations in relapsed tumors
to combinations of targeted therapeutics that were identified through synergy screens.
Subjects will be enrolled into the following treatment groups depending on their
mutation profiles:
Group 1 : Subjects with activating mutations in ALK will receive Ceritinib (ALKinhibitor) + LEE011 (CDK4/6-inhibitor). Ceritinib is a second generation ALK
inhibitor that is more potent than crizotinib, has elicited clinical responses in crizotinibresistant non-small cell lung cancer[121], and has shown efficacy in pre-clinical neuroblastoma models for crizotinib-resistant ALK mutations including F1174L. Dual
CDK4/6 inhibition has been shown to induce cell-cycle arrest and senescence in neuroblastoma cell lines and cell line derived xenografts[122], and unpublished pre-clinical
data indicate that combined ALK- and CDK4/6-inhibition is synergistic.
Group 2 : Subjects with somatic MYCN amplification and/or RAS/MAPK pathway
lesions and/or cell cycle regulatory gene lesions will receive Trametinib (MEK-inhibitor)
+ LEE011 (CDK4/6-inhibitor), a combination which has shown synergy in pre-clinical
models.
Group 3 : Subjects that do not match groups 1 or 2 and whose tumors show wildtype TP53 will receive single-agent HDM201 (MDM2-inhibitor). While the majority of
neuroblastomas have intact p53, increased activity of its principal negative regulator,

61

MDM2, may lead to aberrant p53 signaling in neuroblastoma and present a therapeutic
opportunity[123, 124].
In summary, NEPENTHE represents the first trail of combination therapy that
is targeted to specific mutational profiles that we observed in our recently published
study of relapsed neuroblastoma genomes. Additionally, NEPENTHE will provide an
important opportunity to profile a large number of relapse tumor genomes prospectively,
addressing important sources of bias from our initial study that will yield a more
comprehensive view of the genomic landscape of relapsed neuroblastoma.

3.4.3

Schramm et al. 2015

Concurrent with our study, our German colleagues conducted a similar investigation
on an independent cohort of 16 paired primary and relapsed tumors by whole genome
sequencing, published back-to-back with our manuscript in Nature Genetics earlier this
year[125]. While 2 out of 16 tumors harbored RAS mutations—in HRAS and KRAS,
respectively—the overall prevalence of RAS-MAPK mutations was considerably less
than the 18 out of 23 we observed. Recurrent alterations at relapse included mutations
in the putative CHD5 neuroblastoma tumor suppressor (2 patients), chromosome 9p
losses (5 patients), DOCK8 (6 patients: 2 copy number loss + 4 mutation), inactivating
mutations in PTPN14 (2 patients) and a relapse-specific activity pattern for the
PTPN14 target YAP identified by di↵erential expression profiling[125].
Di↵erences between clinical populations are likely to account for some of the
observed di↵erences between our Eleveld et al. study versus the Schramm et al.
study Indeed, whereas 21 out of 23 patients received chemotherapy prior to relapse
in our combined American/Dutch/French cohort[106], it appears that this was the
case for only 6 out 16 patients in the German study[125]. Chemotherapy is very

62

likely to exert significant selective pressure on neuroblastoma tumors (indeed, we
see evidence of this in Figures 3.7 and 3.9), thereby driving which mutations appear
at relapse. This is an intriguing hypothesis that warrants further study, and data
collected as part of the NEPENTHE trial may shed additional light on this. However,
recent reports that YAP can functionally replace KRAS as a bypass mechanism in
KRAS-addicted cancer[126, 127] opens the possibility that the RAS-MAPK and YAP
pathways identified in our respective studies may in fact be converging on a common
pathway.

3.4.4

The clonal landscape of neuroblastoma

The insight that sub-clonal mutations present in the primary neuroblastoma tumors
can undergo significant clonal enrichment at relapse has prompted us to revisit our
analysis of primary tumor sequencing data generated as part of the TARGET project,
including whole exome sequencing data for 222 primary tumor/blood normal pairs and
targeted gene panel sequencing data for an additional 500 pairs. In order to achieve
higher variant-calling specificity, the initial analysis used an e↵ective variant allele
fraction (VAF) cuto↵ of approximately 10% for variant calling, which can miss low
frequency variants. I have now been able to rerun an analysis of the TARGET data
simply lowering the VAF threshold to 5%, which identified additional mutations in
important neuroblastoma oncogenes such as ALK, KRAS, and NRAS (see Figure
3.12). In fact, our initial estimates of ALK mutation prevalence at 8-9% may need to
be revised upward to at least 10-11%, after accounting for low frequency variants.
We are now designing an ultra-deep targeted sequencing panel in order to better
define the limit of detection for low frequency mutations and to more accurately
estimate the prevalence of clonal and subclonal somatic driver mutations at diagnosis.
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TARGET Validation Cohort, N=500
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Figure 3.12: Comparison of original TARGET analysis to reanalysis of
low frequency variants in 500 tumor/normal pairs. The TARGET validation
sequencing dataset was reanalyzed using VarScan2 with the option “–min-var-freq
0.05” to detect low variant allele fraction (VAF) mutations. As illustrated here, a large
number of driver mutations in important oncogenes such as ALK, KRAS, and NRAS
were missed by the prior analysis, but are detected upon reanalysis.
Similar to our relapse study, we will use statistical analysis to predict whether low
variant frequency is primarily the result of subclonality versus low sample purity.
These e↵orts will have important clinical significance in predicting the proportion of
patients who might benefit from targeted therapies, and may aid in the establishment
of guidelines for minimum depth of coverage for detecting driver mutations from
targeted sequencing.
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Chapter 4

Toward new treatments for
neuroblastoma
4.1

Targeting the GATA2/3-LMO1 signaling axis

Our discovery that rs2168101 modulates LMO1 gene expression in cis by disrupting
a GATA transcription factor binding site has uncovered a GATA2/3-LMO1 signaling
axis in neuroblastoma that can perhaps be exploited therapeutically. Although transcription factors are often thought of as “undruggable” by traditional small molecule
inhibition, their central role in oncogenic signaling makes them attractive targets for
new therapeutic strategies, which include inhibition of transcription factor expression
(e.g. with siRNA or miRNA), inhibition of DNA binding (e.g. with oligodeoxynucleotide
decoys or pyrrole-imidazole polyamides), and epigenetic modulation of transcription
factor function (e.g. BET bromodomain inhibitors)[128]. One relevant and timely example is SB010, a novel anti-GATA3 DNA enzyme therapeutic that has shown promising
results for the treatment of allergic asthma[129]. However, further study is warranted
in order to determine if SB010 may show therapeutic efficacy in neuroblastoma and
to what extent GATA3 inhibition efficacy may depend on rs2168101 genotype—i.e.
to what extent the oncogenic e↵ects of GATA3 are dependent on downstream LMO1
signaling.
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Inhibiting LMO1 directly or targeting its downstream e↵ectors may present another
and potentially more viable therapeutic opportunity. In this regard, our ongoing e↵orts
to map the downstream targets of LMO1 by LMO1 ChIP-seq are crucial, as these
may uncover additional e↵ectors of oncogenic signaling that are more amenable to
small molecule inhibition or other therapeutic modalities. Furthermore, in addition to
the broad strategies outlined above for targeting GATA3, it may be possible to a↵ect
LMO1 signaling through inhibition of protein-protein interactions (e.g. via peptide
aptamer or antibody fragments), a strategy which has shown efficacy when targeted
against the better studied LMO1 paralog, LMO2, in preclinical models[130].
Given that GATA2/3 and LMO1 play important roles in normal cellular processes
in addition to promoting oncogenesis in neuroblastoma, it is unclear if on-target,
o↵-tumor toxicities may limit the therapeutic potential of systemic inhibition of LMO1
signaling. Antibody-directed therapy including drug conjugates and new immunotherapy targeted to neuroblastoma cell surface molecules—including ALK, GD2, and
NCAM, among others—may provide a method to circumvent such toxicities, and
further studies are required to ascertain if and how the cell surface repertoire of
LMO1-driven neuroblastomas di↵ers in comparison to other forms of neuroblastoma.
On the other hand, the recent and rapid development of CRISPR-Cas9 gene editing
technologies[131–133] opens the possibility of targeted enhancer element editing both
in vitro and in vivo, which could be utilized to directly ablate the activity of the
tissue-specific LMO1 enhancer investigated here. However, as concerns rise over the
lack of specificity and o↵-target editing inherent to the CRISPR-Cas9 system[134],
the development of novel nuclease dead CRISPR-Cas9 proteins fused to chromatin
remodelers[135, 136] may provide another therapeutic opportunity to ablate LMO1
enhancer activity through targeted editing of the epigenome without the inherent risks
associated with DNA-editing.
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4.2

New therapies for relapsed neuroblastoma

Our identification of RAS pathway activation in a substantial fraction of neuroblastomas that relapsed on chemotherapy indicates that targeting the RAS pathway
may provide a route to rational therapy when more traditional treatments fail. Indeed,
the RAS pathway has long been viewed as an attractive target for new therapies due
the high prevalence of RAS-activating mutations in cancer more broadly: approximately one-third of solid tumors and one-fifth of myeloid malignancies[137]. Much of
the biochemistry of RAS-signaling has been worked out, and it is now understood
that RAS proteins are guanine binding proteins (G proteins) where dynamic cycling between GTP- and GDP-bound states regulates cellular proliferation in normal
physiology; to summarize, the GTP-bound state induces conformational changes in
RAS that activate additional downstream growth signaling e↵ectors whereas GDPbinding is suppressive[137]. And yet despite these biochemical insights and over three
decades of intense research, e↵ective rational therapies targeting the RAS pathway
have largely eluded the cancer community. Attempts to drug the GTP-binding site of
RAS have proven considerably less fruitful than inhibiting tyrosine kinases via their
ATP-binding domains, due to the comparatively high picomolar affinity for GTP, the
high intracellular abundance of GTP, and the lack of apparent druggable allosteric
sites[137].
Due to the difficulty of inhibiting RAS directly, many alternative strategies are
being explored to treat RAS-mutated cancers, including targeting downstream RAS
e↵ectors, targeting RAS localization, targeting synthetic lethal partners of RAS,
and immune-based therapies, though none of these have yet yielded robust clinical
responses[137]. Indeed, our studies of single-agent MEK inhibition in RAS-pathway
activated neuroblastoma cell line models elicit cytostatic responses that delay but
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do not prevent eventual tumor outgrowth (Figure 3.10). Our laboratory is therefore
actively investigating combination therapies, and we have performed synergy screens
in order to identify drug combinations that exhibit superadditive anti-tumor e↵ects in
RAS pathway activated neuroblastoma. These e↵orts identified combined ALK and
CDK4/6 inhibition (ceritinib + ribociclib) as a potent combination for ALK-mutated
neuroblastomas, as well as combined MEK and CDK4/6 inhibition (trametinib +
ribociclib) as a potent combination for neuroblastomas that are MYCN -amplified
and/or harbor other non-ALK lesions in the RAS-MAPK pathway. Remarkably, CDK4
was recently identified as a synthetic lethal partner of KRAS in non-small cell lung
cancer[138] and was also identified as the principal driver of the molecular di↵erences
between the genetic and pharmacological perturbation of NRAS in melanoma[139],
suggesting an integral link between CDK4 signaling and RAS signaling more broadly.
In addition to our discovery of a high prevalence of RAS-MAPK activating mutations
in relapsed neuroblastomas, these results provide the rationale for using exactly these
combinations in patients with appropriately matched genomic lesions in the soon to
open NEPENTHE phase 1b/2 clinical trial.
Although these data give us cautious optimism that we can prolong survival
for relapsed neuroblastoma, the lack of permanent responses to combined MEK and
CDK4/6 inhibition in our preclinical studies suggests that new treatment strategies will
likely be required for curative therapy in patients with RAS-MAPK activation in the
absence of ALK mutations. In the relative short term, higher order drug combinations
can be investigated for their potential to induce even better clinical responses. Longer
term, the development of entirely new treatment approaches have the potential to
revolutionize the field of RAS-targeted therapy, including new allosteric inhibitors
that directly target mutated RAS (for example, a novel inhibitor that covalently
and allosterically modifies mutant KRAS G12C to preferentially bind inactivating
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GDP[140]) and the emergence of new immunotherapies (for example, an anti-GD2
therapy recently approved for high-risk neuroblastoma[8]). Indeed, targeting RAS
has recently experienced a resurgence in interest both in academia and industry,
culminating in the launch of NCI RAS Initiative in 2013, with the hope of uncovering
new and transformative therapies[141].
In the immediate term, basic questions still remain concerning how RAS pathway
activating mutations arise and evolve clonally in neuroblastoma, which are likely to
have therapeutic implications. The higher prevalence of RAS-MAPK mutations in
relapsed neuroblastoma observed in our study[106] in comparison to our German
colleagues[125] may originate from much higher rates of chemotherapy treatment
in our cohort or other biases in sample collection. It will therefore be important to
better ascertain the prevalence of RAS-MAPK activating mutations prospectively
through e↵orts such as our NEPENTHE trial, and sequencing could be more broadly
incorporated into our pre-clinical treatment models (e.g. cell line or patient derived
xenografts) to better understand the molecular correlates of drug resistance and how
they evolve over the course of treatment. Rapid progress has been made in developing
single cell DNA and RNA sequencing technologies in recent years[142], which could
be applied to achieve an even finer resolution view of the clonal evolution events that
underlie neuroblastoma relapse and treatment resistance. In light of our observation of
RAS-MAPK activating mutations at relapse that are undetectable even by ultra-deep
sequencing in matched primary tumor biopsies, it is an open question whether or not
adding ALK and/or MEK and/or CKD4/6 inhibition as frontline therapy could be
used to anticipate and/or prevent the outgrowth of RAS-MAPK activated subclones
when they are undetectable at diagnosis. All of these questions provide interesting
avenues for future studies.
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4.3

Final remarks

In conclusion, the field of neuroblastoma genomics has experienced rapid progress in
just the past 5-10 years, with key advances including the discovery of causal mutations
for familial neuroblastoma, discovery of common variation associated with sporadic
disease, mapping the somatic coding landscape of neuroblastoma primary tumors, and
the emergence of mutated ALK as a therapeutic target for rational therapy. However,
much work remains to be done to understand how germline and somatic lesions interact
to promote tumor initiation and maintenance, to elucidate the epigenetic landscape
of disease subtypes, to better define the temporal evolution of neuroblastoma during
tumor initiation and under di↵erent treatment modalities, and to ultimately develop
new therapeutic strategies for the majority of neuroblastomas which lack traditionally
“targetable” mutations and for relapsed disease.
The studies that constitute this dissertation begin to address some of these important questions and provide a blueprint for progress in the field. The identification
of a causal high-risk-associated germline variant in a LMO1 super-enhancer has laid
the groundwork for comprehensive epigenomic profiling e↵orts to understand the
regulatory landscape of neuroblastoma, generating data that is likely to reveal insights
into LMO1 function specifically, genome-scale regulatory architecture more broadly,
and provide insights into the function of non-coding mutations. The discovery of
clonal evolution of RAS-MAPK mutations in relapsed neuroblastoma is now directing
e↵orts to better define the subclonal makeup of neuroblastoma tumors as well as an
early phase clinical trial of MEK-inhibitors in relapsed neuroblastoma. In the coming
years, we are hopeful that these studies will be looked back upon as crucial steps
toward a comprehensive understanding of the molecular basis of neuroblastoma and
the development of better treatments for this aggressive childhood malignancy.
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Appendix A

Statistical methods for estimating
subclonality of point mutations
from NGS data
A.1

ABSOLUTE: Carter et al. 2012

Published in 2012, ABSOLUTE was a first-in-class algorithm developed to aid in
the estimation of clonal versus subclonal mutations detected by NGS experiments from
cancer samples [107]. Because tumor purity and ploidy are important confounders in
the inference of mutation clonality, the primary goal of ABSOLUTE is to jointly infer
the purity and ploidy from NGS data and to discern clonal versus subclonal events.
The theoretical framework of ABSOLUTE is summarized in what follows.
For simplicity, we consider a mixed population which includes a fraction ↵ of a
clonal cancer cell population and a fraction (1

↵) of contaminating normal cells; in

the idealized case the normal cells will be diploid (copy number = 2) across the whole
genome. Let q(x) denote the absolute integer copy number at locus x in the cancer
cells. The average tumor “ploidy”, ⌧ , is therefore the absolute copy number averaged
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over the N segmented loci across the whole genome:

⌧=

N
X

w(x)q(x)

x=1

where the weight of each locus, w(x) scales proportionally to the size of the locus in
base pairs. The relative copy number, R, of locus x can be expressed as:

R(x) =

2(1 ↵) + q(x)↵
2(1 ↵) + ⌧ ↵

For a somatic point mutation (e.g. SNV, indel, or SV breakpoint) at locus x, we can
express the expected fraction of mutant alleles, F , as follows:

F (x) =

2(1

s(x)↵
=
↵) + [q(x) s(x)]↵ + s(x)↵
2(1

s(x)↵
↵) + q(x)↵

where s(x) represents the absolute copy number of the mutation (aka “somatic multiplicity”), 2(1
[q(x)

↵) represents the relative weight of DNA originating from normal cells,

s(x)]↵ represents the relative weight of non-mutant DNA originating from

cancer cells, and s(x)↵ represents the relative weight of mutated DNA originating
from cancer cells. Note that 1  s(x)  q(x) generally, but that s(x) < q(x) will hold
assuming that the mutation only arose once in the evolutionary history of the cancer
and that LOH has not occurred. Practically speaking, the quantities R(x) (relative
copy number) and F (x) (mutant allele fraction) can be easily and directly estimated
by NGS, whereas q(x) and s(x) are the quantities of biological interest that are less
straightforward to estimate, with ↵ and ⌧ as nuisance parameters.
Within this framework, R(x) =

2(1 ↵)
2(1 ↵)+⌧ ↵

for clonally homozygously deleted sites—

i.e. q(x) = 0. For adjacent copy-number states – i.e. for each unit increase in q(x)
– it follows that R(x) will correspondingly increase by
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↵
.
2(1 ↵)+⌧ ↵

Outliers from this

pattern are inferred to be “subclonal” CNAs. At a fixed q(x), a similar pattern exists
for clonal SNVs – i.e. F (x) =

s(x)↵
2(1 ↵)+q(x)↵

for s(x) 2 {1, 2, ..., q(x)} – and outliers from

this pattern are inferred to be “subclonal” SNVs.

A.2

Extending ABSOLUTE: Landau et al. 2013

In Landau et al. 2013, this framework was extended to estimate the cancer cell
fraction (CCF) of SNVs (CCF is the fraction of tumor cells harboring a presumed
subclonal mutation) rather than simply call presence of such mutations as outliers [108].
Their method specifically applies to subclonal SNVs that may arise within a nonCNA or clonal CNA region, resulting in unit somatic multiplicity (s(x) = 1) under
the parsimonious assumption that the SNV mutation only arose once within the
evolutionary history of a specified tumor (Figure A.1). As a function of the CCF, c,
the expected fraction of mutant alleles will therefore follow the equation:

F (c) =

↵c
↵) + q(x)↵

2(1

Thus, for a particular SNV with a specified CCF equal to c, the likelihood of observing
a mutant alleles out of n total sequencing reads equals

P [A = a|C = c, N = n] = Binomial(a; n, p = F (c))

so that

P [C = c|A = a, N = n] / Binomial(a; n, p = F (c))
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Figure A.1: Two examples of sequential tumor evolution. (Top) In this example,
copy-number gain precedes somatic point mutation at a given locus x, resulting in
copy-number q(x) = 3 and somatic multiplicity s(x) = 1. (Bottom) In this example,
somatic point mutation is followed by sequential gain of the mutated allele at a given
locus x, resulting in copy-number q(x) = 3 and somatic multiplicity s(x) = 2.
will hold under a uniform prior on C 1 . In practice, ↵ and q(x) are estimated by
ABSOLUTE or related algorithms (our laboratory prefers the Sequenza algorithm [109],
due to ease of use) whereas a and n are measured directly from NGS data. The
distribution of C is then computed using a single variable grid approach.

1

Equivalently, a uniform prior implies that F (C) follows a Beta(a + 1, n a + 1) distribution that
is right-truncated at F (1) due to the 0  c  1 constraint. Therefore, the conjugate prior for F (C)
will be another Beta(a0 , b0 ) distribution that is truncated at F (1), with a corresponding truncated
Beta(a + a0 + 1, n + b0 a + 1) posterior. Thus, a0 and b0 can be interpreted as “pseudocounts” for
mutant and wild-type reads, respectively. While we consider F (C) here primarily for mathematical
convenience, note that F is a simple scaling function with respect to C, so that the posterior and
conjugate-priors for C = F 1 (F (C)) are simply re-scaled versions of the distributions just described.
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Appendix B

Methods for Oldridge, Wood et al.
2015
Genotype imputation and association testing
A primary European-American cohort of 2,101 cases and 4,202 matched controls
were assayed with Illumina HumanHap550 v1, Illumina HumanHap550 v3, and Illumina Human610 SNP arrays as previously described[51]. Genotypes were phased using
SHAPEIT v2.r790 and data from 1000 Genomes phase 1 version 3. Subsequently, imputation was performed using IMPUTE2 v2.3.1 for all SNPs and indel variants annotated
in the 1000 Genomes phase 1 version 3. Testing for association with neuroblastoma
under an additive genetic e↵ect model was performed using the frequentist likelihood
score method implemented in SNPTEST v2.4.1. Genotypes for a previously described
African-American cohort of 365 cases 2491 controls[143] were imputed and tested for
neuroblastoma association using the same analytic pipeline. Statistical adjustment for
gender was performed in both cohorts. For population stratification adjustment, the
first 20 multidimensional scaling (MDS) components were included as covariates in
the European-American cohort, while a measure of African admixture as estimated
by the ADMIXTURE software program was used in the African-American cohort.
Manhattan plots of SNP position and statistical significance were generated using
LocusZoom software. Linkage plots were generated by Haploview software based on
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HapMap CEU individuals (version 3, release 2) using default settings. All research
subjects or their guardians provided informed consent for research, and all institutions
involved in this research had regulatory approval for human subjects research.
Prioritization of candidate causal variants
All SNPs and indels reported in the 1000 Genomes phase 1 version 3 data were
considered as candidate causal variants and were ranked based on a combination
of (1) neuroblastoma association in the primary European-American cohort, (2)
evolutionary conservation, (3) DNase I hypersensitivity, and (4) transcription factor
binding motif matching. Neuroblastoma association in European-Americans was
evaluated as described above. Conservation scores were computed as the average of
the phastCons46wayPlacental UCSC conservation track score for all bases from the
10 position to the +10 position surrounding each candidate variant. A DNase I
hypersensitivity score was calculated by counting the number of sequencing tags from
the

100 position to the +100 position around each candidate variant in ENCODE

data for the neuroblastoma cell line, SK-N-SH. Position weight matrices representing
transcription factor binding motifs were obtained from the JASPAR database, and
candidate binding sites were identified by scanning the hg19 human reference genome
using the MATCH-TM algorithm with a matrix similarity score (mSS) threshold of
0.90.
Neuroblastoma association replication and meta-analysis for rs2168101
We replicated the association of rs2168101 with neuroblastoma by direct genotyping
of rs2168101 in independent Italian (cases = 420, controls = 751) and UK cohorts
(cases = 369, controls = 1109). Meta-analysis across the European-American, AfricanAmerican, Italian and UK cohorts was performed using the inverse variance method
provided in the METAL software program. Beta values (log-odds) and standard errors
generated by SNPTEST, as described above, were used as input.
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Survival analysis
We compared both overall survival and event-free survival over a 10-year followup period between G/G versus G/T and T/T rs2168101 genotypes in a case-case
comparison between neuroblastoma patients from the European-American cohort.
Because rs2168101 genotypes were imputed in this cohort, the most-probable genotype
predicted by IMPUTE2 was used for each patient. In the event of insufficient followup, all data was right censored. Cox proportional hazard modelling was performed
using 20 MDS components to account for population stratification, in addition to
MYCN amplification status, as covariates. All statistical analysis and generation of
Kaplan-Meier plots was performed in R using the CRAN repository package, “survival”.
Total and allele-specific expression analysis
Total and allele-specific RNA expression analysis was performed based on poly-Aenriched RNA-sequencing data from 127 primary neuroblastoma tumours sequenced
through the TARGET project. RNA-seq reads were aligned to the hg19 human
reference genome using the STAR aligner (v2.4.0b). Aligned reads were assigned to
RefSeq genes using HTSeq (v0.6.1) and normalized to RPKM for total gene expression
measurements. DNA genotypes for rs2168101 were obtained either through matched
whole-genome sequencing (n = 69) or targeted genotyping assays (n = 58 additional
tumours). DNA genotypes for rs3750952 were obtained through either matched wholegenome or whole-exome sequencing.
Allele-specific RNA expression analysis was performed from a subset of 45 primary
neuroblastoma tumours (out of 127) with the necessary synonymous exonic SNP
genotypes (rs3750952 = C/G) to enable measurement of allelic expression by mRNAseq. As a readout for allelic imbalance of rs3750952, we computed allelic fractions as
min(C, G)/(C + G), since phasing between rs3750952 and rs2168101 alleles in each
tumour was unknown. Statistical comparison between the two groups was performed
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by two-sided Welch’s t-test, comparing 12 tumours heterozygous for rs2168101 (G/T)
to the remaining 33 tumours that were homozygous for rs2168101 (G/G) as controls.
DNA genotyping for rs2168101 was performed by whole-genome sequencing or a
directed genotyping assay, whereas DNA genotyping for rs3750952 was determined
from TARGET whole-exome or whole-genome sequencing. Where possible, integrity of
sample matching was verified by measurement of genome-wide genotype concordance.
All genotypes are reported with respect to the minus strand of the human reference
genome, hg19.
To measure allele-specific expression directly at the intronic SNP we first purified
the nuclear RNA fraction using the Cytoplasmic and Nuclear RNA purification Kit
(Norgen Biotek, 21000) from four neuroblastoma cell lines (SNP rs2168101: SHSY5Y =
G/G; NLF = G/T; NGP = G/G; NB1643 = T/T). Ion AmpliSeq Designer v3.4.3 (Life
Technologies White Glove service) was used to design amplicons targeting the intronic
SNP rs2168101 and three additional exonic SNPs in linkage disequilibrium. Custom
AmpliSeq libraries were prepared in triplicate for each cell line, indexed, pooled and
sequenced using an Ion 318 Chip on a Personal Genome Machine (Life Technologies).
Reads were aligned to the hg19 reference genome and a synthetic genome showing the
alternate allele at SNP rs2168101 at hg19 chr11:8255408 to account for any alignment
bias. High-quality mapped reads containing the reference G allele or alternative T
allele were counted and tested for significant deviation from 50:50 expression using a
two-sided one-sample t-test (null hypothesis that allele fraction = 0.50) across three
experimental replicates. Primer pair sequences:
For rs1042359:
forward: 5’-GTGTGGGAGACAAAUTCTTCCUGA-3’,
reverse: 5’-GCCGGGCGUTACTGAACUT-3’;
For rs3750952:
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forward: 5’-CGCAAGAUCAAGGACCGCTAUC-3’,
reverse: 5’-GATGAGGTUGGCCTTGGTGUA-3’;
For rs2168101:
forward: 5’-CCUTTCCUGAAGGAGCGCAAA-3’,
reverse: 5’-CACTTTCCATUAAGGAGATAGCAUCCC-3’;
For rs204929:
forward: 5’-CAAUCTAGGTUAAGAGCCGGACAAG-3’,
reverse: 5’-GTGUCCAGCCGCAGCUA-3’.
Reporter assays
Primers were designed to clone a 553-bp genomic region (hg19, chr11:82551558255707) surrounding the candidate SNP rs2168101 at the GATA transcription factor
binding site from neuroblastoma cell lines SKNSH (G/G) and matching site of BE2C
(T/-). The cloned region did not contain other statistically significant SNPs at the
LMO1 locus. The primers were designed to introduce sequences for restriction sites
5’-XhoI and 3’-BglII, which are present in the MCS of pGL4.26[luc2/minP/Hygro]
(Promega, E8441). XhoI/BglII restriction enzyme digested fragments were sequence
verified, gel purified, ligated into pGL4.26[luc2/minP/Hygro], transformed into One
Shot TOP 10 chemically competent cells (Life Technologies, C4040-10) and grown
on LB plates containing 50 µg ml-1 ampicillin overnight at 37 C. Colonies positive
for the vector containing the insert were grown in 50 ml LB broth containing 50
µg ml-1 ampicillin and plasmids were purified using a Qiagen Plasmid Midi Prep
Kit (Qiagen, 12143). Transfection into HEK293 cells which were approximately 50%
confluent was accomplished using Fugene 6 Transfection reagent (Promega E2691) at
a 3 µl:1 µg fugene:DNA ratio. Cells underwent selection in 150 µg ml-1 Hygromycin B
(Mediatech, 30-240-CR) and individual colonies were picked and grown, and genotypes
of constructs were confirmed by fragment size and Sanger sequencing. Subsequently,
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HEK293 + 553 bp insert cells and HEK294 + vector only cells were grown in 96-well
optical plates. On day 2, the cells were transiently fugene transfected with the Renilla
expression control vector pGL4.74[hRLuc/TK] (Promega, E6921) at a 1:500 dilution
with respect to the luciferase vector. Luciferase assays were carried out 48 h after
Renilla transfection using Dual Luciferase Reporter Assay System (Promega, E1910)
with read-outs performed on a Dual Injector System for GloMax-Multi Detection
System (Promega, E7081). Luciferase expression was normalized to Renilla expression.
All reporter assays were performed in quintuplicate (five technical replicates each)
across the experimental conditions: (1) HEK293T, (2) HEK293T with empty vector,
(3)-(6) four independent clones of HEK293T with T-allele construct, and (7)-(10) four
independent clones of HEK293T with G allele construct. Results were averaged across
technical replicates, normalized to empty vector, and reporter activities for T allele
versus G allele clones (four biological replicates each) were analysed by two-sided
Welch’s t-test.
Construct risk allele (G):
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCC
ACATCCTGAGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTATTC
TGCTGGGCCCAGCGCATGCATCTGAGTGTGTGCCCAGGCGTGCGTGTCG
GCGCAAACATCATCCATTGTGAAATATCAGTGTTTTCATGGGTGAGTAG
TAATTACTGGGTAATGCTTTAAAACCTTTCCTGAAGGAGCGCAAAGCCA
TTTTTTTCTAAAGTCAGGAGTACATTAAAAGGATTACCATGTAGATTTG
ATTTTTAGATAACACTAAAATGGATCCCAAATGGACTTCAGCAAAGGGA
TGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTCAGGTCCCAGAG
CCAGGCTGGGGAAGGAGGGAGGGAAGAGGTGTCTGCAGGGGGGCAGGC
TGGCAGATTGGGTGGGGGCTAGGTGGGAATGGGGAAGGCAGAGCAGGA
GGGAGGGCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCAG
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GAGACTACAGAGCCCCT
Construct protective allele (T):
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCC
ACATCCTGAGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTATTC
TGCTGGGCCCAGCGCATGCATCTGAGTGTGTGCCCAGGCGTGCGTGTCG
GCGCAAACATCATCCATTGTGAAATATCAGTGTTTTCATGGGTGAGTAG
TAATTACTGGGTAATGCTTTAAAACCTTTCCTGAAGGAGCGCAAAGCCA
TTTTTTTCTAAAGTCAGGAGTACATTAAAAGGATTACCATGTAGATTTG
ATTTTTATATAACACTAAAATGGATCCCAAATGGACTTCAGCAAAGGGA
TGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTCAGGTCCCAGAG
CCAGGCTGGGGAAGGAGGGAGGGAAGAGGTGTCTGCAGGGGGGCAGGC
TGGCAGATTGGGTGGGGGGCTAGGTGGGAATGGGGAAGGCAGAGCAGG
AGGGAGGGCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCA
GGAGACTACAGAGCCCCT
Cell culture and protein lysates
Jurkat T-ALL and neuroblastoma cell lines were sourced from the American
Type Tissue Culture Collection, and kept in growth medium of RPMI+10% heatinactivated FCS with 1% penicillin-streptomycin, as previously described[81]. Cells
were lysed for protein, with subsequent protein quantified by spectrophotometry, as
previously described[144]. Protein was resolved on 8-14% Tris-Bis gels, transferred to
PVDF membranes, blocked and subjected to primary and secondary antibodies, as
previously described[144]. Primary antibodies were anti-GATA3 (Pierce Biotechnology,
1:1,000), anti-LMO1 (Bethyl Laboratories, 1:1,000) and ↵-tubulin (Cell Signaling
Technologies, 1:1,000). Blots were developed with secondary horseradish peroxidase
(HRP)-conjugated antibodies (Cell Signaling Technologies, 1:5,000) and Protein-plus
Dura ECL Reagent (Thermo-Fisher Scientific). All cell lines are genotyped semiannually
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to assure identity and also tested routinely for mycoplasma contamination.
Genome-wide occupancy analysis
ChIP coupled with massively parallel DNA sequencing (ChIP-seq) was performed
as previously described[145, 146]. The following antibodies were used for ChIP: antiH3K27ac (Abcam, ab4729) and anti GATA3 (Santa Cruz, sc-22206X). For each ChIP,
10 µg of antibody was added to 3 ml of sonicated nuclear extract. Illumina sequencing,
library construction and ChIP-seq analysis methods were previously described[146].
ChIP-seq processing
Reads were aligned to build hg19 of the human genome using bowtie with parameters -k 2 -m 2 -e 70 -best and -l set to the read length[147]. For visualization in the
UCSC genome browser[148] in Figures 2.11a and 2.12a, WIG files were created from
aligned ChIP-seq read positions using MACS 1.4.2 with parameters -w -S -space = 50
-nomodel -shiftsize = 200 to artificially extend reads to be 200 bp and to calculate
their density in 50-bp bins[149]. Read counts in 50-bp bins were then normalized to
the millions of mapped reads, giving reads per million values.
ChIP-seq allele specificity analysis
To determine preferential ChIP-seq coverage of one allele, which implies preferential
binding of protein to one allele vs. another, we counted the reads at rs2168101 using
samtools mpileup[150]. By using the aligned reads described above, this gave us a
count of reads with a given base at this position. The fraction of reads with the
risk allele versus the protective allele is reported in Figure 2.11b. Statistical tests for
preferential allelic binding were performed by two-sided binomial test.
Enriched regions
Regions enriched in ChIP-Seq signal were identified twice using MACS with
corresponding control and parameters -keep-dup = all and -p 1e-9 or -keep-dup = 1 and
-p 1e-9. Super-enhancers in SHSY5Y and KELLY were identified using ROSE (https:
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//bitbucket.org/young_computation/rose[86, 151] with modifications based on ref.
[82]. In brief, peaks of H3K27ac were identified using MACS as described above and their
union was used as constituent enhancers. These peaks were stitched computationally
if they were within 12,500 bp of each other, although peaks fully contained within
± 2,000 bp from a RefSeq promoter were excluded from stitching. These stitched
enhancers were ranked by their H3K27ac signal (length ⇥ density) with input signal
in the corresponding region subtracted. Super-enhancers were separated from typical
enhancers by geometrically determining the point at which the line y = x is tangent
to the curve of stitched enhancer rank versus stitched enhancer signal. Those stitched
enhancers above this point are considered super-enhancers.
To account for the known focal amplification of the MYCN locus in KELLY,
BE2, BE2C and NGP neuroblastoma cells, which contain enhancers, we modified our
pipeline slightly. Because MACS is insensitive for the identification of peaks in focally
amplified DNA, we identified peaks of H3K27ac versus input using MACS2 callpeak
(https://pypi.python.org/pypi/MACS2) with parameters -broad -keep-dup = 1 p 1e-9 and -broad -keep-dup = all -p 1e-9. The union of these MACS2 calls was
used as constituent enhancers for ROSE with the remaining parameters as described
above. For Figure 2.12b, most of the curve represents the analysis performed using
MACS-identified constituents; the rank and signal of the MYCN-associated enhancer
comes from this MACS2-identified set of constituents to remain consistent with the
conclusions and methods as previously described[82]. The curve output from the
MACS-identified enhancers was vertically compressed and a point representing the
signal of the MYCN-associated super-enhancer from the MACS2-identified enhancers
was added in Illustrator. Super-enhancers were assigned to the single expressed
RefSeq transcript whose transcription start site was nearest the centre of the stitched
region. Expressed genes were in the top 2/3 of RefSeq transcripts ranked by their
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promoter (transcription start site ± 500 bp) H3K27ac signal determined by bamToGFF
(https://github.com/BradnerLab/pipeline) with parameters -e 200 -m 1 -r -d.
Clone cell generation
LMO1 cDNA was amplified from pcDNA3-LMO1 and subcloned into the XhoI
and NotI site of the lentiviral vector pOZ-FHN. Lentivirus expressing FH-LMO1 was
propagated in HEK293T cells by cotransfection with psPAX2 and pMD2.G plasmids
(adgene) using FUGENE 6 (Roche) by standard methodologies[152]. Viral supernatant
was recovered and KELLY cells were infected with lentivirus expressing FH-LMO1 or
empty vector alone, as previously described[81]. Cells were sorted for expression of
the IL2R, and positive expression was used to establish single cell clones. Expression
of FH-LMO1 was assessed by western blotting as above to confirm overexpression.
siRNA and growth assays
SHSY5Y, KELLY and KELLY clone cells were reverse transfected with 100 nM
concentrations of either non-targeted (control siRNA-1) or GATA3-targetted siRNA-1
or -2 (Ambion) for 6 h with lipofectamine 2000 (1:1,000) in Optimem I before being
replated into growth assays in normal RPMI growth media. Cells (2 ⇥ 105 ) were
replated in triplicate for counting at 24, 48 and 72 h post-transfection by manual
hemocytometry. Cells (5 ⇥ 105 ) were replated for protein lysates at the same time
points. All experiments were repeated in triplicate, with a technical replicate number
of 9 for all cell growth assays as described[153]. Statistical tests were performed by
two-sided Welch’s t-test.
Data access
GWAS and sequencing data used for this analysis are available in dbGaP under accession phs000124 and phs000467. The tumour genomics data are also available through
the Therapeutically Applicable Research to Generate E↵ective Treatments (TARGET)
data matrix portal (http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.
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html). Data generated through the ENCODE project including DNase I hypersensitivity sequencing and ChIP-sequencing data were obtained from ftp://hgdownload.cse.
ucsc.edu/goldenPath/hg19/encodeDCC/. Aligned sequencing read (bam) files were
used as provided from the FTP site. The mammalian evolutionary conservation track
representing 46 mammalian species (phastCons46wayPlacental) was obtained from
the UCSC Table Browser http://genome.ucsc.edu/cgi-bin/hgTables?command=
start. JASPAR-annotated transcription factor binding site position frequency matrices were obtained from http://jaspar.genereg.net/html/DOWNLOAD/JASPAR_
CORE/pfm/nonredundant/pfm_all.txt. New ChIP-seq data sets generated in this
study are available under super series GSE65664.
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Appendix C

Methods for Eleveld, Oldridge,
Bernard et al. 2015
Sample collection and patient selection.
The inclusion criteria for this study were histopathological confirmation of neuroblastoma at original diagnosis and the presence of biopsy material from a subsequent
relapse specimen. Patients were included in this study after obtaining informed consent
from parents or guardians, with oversight from the ethics committees ‘Comité de
Protection des Personnes Sud-Est IV’, reference L07-95/L12-171, and ‘Comité de Protection des Personnes Ile-de-France’, reference 0811728 in France, the review board at
the Children’s Hospital of Philadelphia and review boards at other Children’s Oncology
Group sites that submitted samples for patients on this study in the United States,
and the review board of the Academic Medical Center of the University of Amsterdam
in the Netherlands. Somatic ALK mutation status has been reported for samples
FR NB0175, FR NB308, FR NB399, FR NB1224, FR NB1269 and FR NB13821[104].
Whole genome sequencing, summary.
Whole-genome sequencing was performed by Complete Genomics to an average coverage of 50x per sample (for Dutch and US patient material and cell line material)[154]
or using Illumina HiSeq 2500 instruments to an average coverage of 80x per sample (for
French patient material). Material for each patient (lymphocytes, primary tumor and
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relapse tumor) was in all cases sequenced using the same sequencing platform. Estimation of normal tissue contamination and whole-genome segmentation was performed
on all primary-normal and relapse-normal pairs with Sequenza software v2.1.0 using
both binned coverage ratio data and SNV allelic ratios as input[109]. Coverage-based
copy number plots were generated as previously described[44], with the exception
that values were corrected for ploidy and purity as determined by Sequenza. The R2
bioinformatics platform and Circos[155] were used for analysis and visualization.
Whole genome sequencing, Complete Genomics.
Potential somatic variants were determined with the CallDi↵ algorithm with somatic
output as available in the CGAtools v1.3.0 package, maintained by Complete Genomics.
Every tumor was compared to its matched blood sample across the genome. The
somatic output files were then filtered to regions where coding sequences are defined
in the UCSC re✏at. Silent mutations were subsequently removed from the analysis. In
addition, we determined the presence of somatic splice-site variants in the three bases
surrounding exons as defined by UCSC re✏at data. Variants with a somatic score
> 0.05 (for NL 041, NL 571 and NL N607) or Somatic Quality high (the remainder of
the patients) were included in the analysis.
Comparisons of structural variants between tumor and lymphocyte genomes were
performed with the JunctionDi↵ and Junction2Event algorithms from CGAtools. These
somatic events were filtered to remove events matching the following criteria: events
annotated as artifacts, footprints smaller than 70 bases, less than 10 discordant mate
pairs, under-represented repeats and presence in a set of baseline genomes (as provided
on the website of Complete Genomics (B36baseline-junctions.tsv)). Of the remaining
entries, we kept the following events: (i) exon bites, where both ends of a junction
were within the same gene and in addition a↵ect an exonic sequence, (ii) breaks
by inversion, where both ends of a junction land within a gene, thereby damaging
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both genes but leaving the genes in between una↵ected, (iii) potential fusion genes,
which are strand matched, where both ends of a junction landed within a gene and
the resulting end product fit in terms of orientation of both genes, and (iv) regions
(deletions or (tandem) duplications) of up to 1 Mb, containing up to five genes.
Whole genome sequencing, Illumina.
Whole-genome sequencing was performed using an Illumina HiSeq 2500, with 90-bp
paired-end reads for six tumors and 100-bp paired-end reads for the remaining two tumors. After alignment with hg19 using Burrows-Wheeler Aligner (BWA)[156], bam files
were cleaned according to Genome Analysis Toolkit (GATK) recommendations[157].
Variant calling was performed in parallel using three variant callers: GATK 2.2-16,
SAMtools 0.1.18 and MuTect 1.1.430 (refs. [150, 157, 158]). ANNOVAR v2012-10-23
(ref. [159]) with COSMIC v64 and dbSNP v137 was used for annotation. SNVs with a
quality under 30, a depth of coverage under 6 or with fewer than 2 reads supporting the
variant were filtered out, as were variants reported in more than 1% of the population
in the 1000 Genomes Project[160] or Exome Sequencing Project (Exome Variant
Server, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing
Project (ESP)).
Variants were then filtered to those regions where coding sequences are defined or
to variants in the three bases surrounding exons. Silent mutations were subsequently
removed from the analysis. Tumor and corresponding constitutional genomes were
compared using the SAMtools mpileup algorithm[150], and non-somatic variants were
discarded from the analysis.
Structural variants, including deletions, inversions, tandem duplications and translocations, were analyzed using DELLY v0.5.5 with standard parameters[161]. In tumors,
at least ten supporting reads were required to make a call, and five supporting reads
were required for sample NB0175 with a coverage of only 40x. To predict structural
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variants in constitutional samples for subsequent somatic filtering, only two supporting
reads were required. To identify somatic events, all the structural variants in each
normal sample were first flanked by 500 bp in both directions and any structural
variant called in a tumor sample that was in the combined flanking regions of the
respective normal sample was removed. Deletions with more than five genes a↵ected
or larger than 1 Mb in size and inversions or tandem duplications covering more
than four genes were removed. We focused on exonic and splicing events for deletions,
inversions and tandem duplications. For translocations, we kept all structural variants
that occurred in intronic, exonic, 5’ UTR, upstream or splicing regions.
Clonality analysis.
Estimation of the cancer cell frequency of somatic mutations was performed using
the Bayesian method of Carter et al. to infer posterior intervals without clustering for
comparison[107]. Namely, we assumed that the expected allele fraction of a mutation in
a sample of tumor purity “↵”, total somatic copy number q, and mutation multiplicity
s can be expressed as a function of the cancer cell fraction c: f (c) = ↵cs/(2(1 ↵)+↵q).
Given a uniform prior on c, the posterior density of c is therefore proportional to
Binom(a|N, f (c)), where a is the variant read count and N is the total read count.
While ↵ and q are estimated by Sequenza, the mutation multiplicity s is generally not
known. However, under the parsimony assumption that a mutation occurs only once
within a tumor’s evolutionary history, we can bound s by 1  s  m  q, where m is
the major allelic copy number of the mutation locus, which is estimated by Sequenza.
We therefore modeled the posterior distribution under two assumptions: s = 1 (biased
toward higher clonality estimates) as well as s = m (biased toward lower clonality
estimates).
Estimation of CCF was also performed using PyClone v0.12.7 as an alternative
method for comparison[162]. For each primary or relapse tumor, PyClone was run on
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all somatic coding point mutations using the “parental copy number” method and
“pyclone beta binomial” density, with estimates of tumor purity and allelic copy number
from Sequenza provided as necessary inputs. The Markov Chain Monte Carlo (MCMC)
step of PyClone was run for 10,000 iterations with burn-in and thin parameters set to
1,000 and 10, respectively, resulting in 900 independent samples from the posterior
distribution of cancer cell fraction per mutation. Otherwise, default options for PyClone
were used.
Cancer mutation analysis.
To identify pathways or processes that were frequently a↵ected in neuroblastoma
relapse tumors we used the CancerMutationAnalysis R package[110]. Somatic mutations detected only in the relapse and detected in the relapse and primary for all
tumors were used as input. This algorithm is not suitable for the analysis of structural
variants, so these were not included in this analysis. P -values were generated using the
permutation null method without heterogeneity and signify enrichment of mutated
genes associated with a certain Gene Ontoloty (GO) Biological Process category across
all relapse tumors.
Cell lines.
All cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% FBS, 20 mmol/L L-glutamine, 10 U/mL penicillin, and 10
µg/mL streptomycin and maintained at 37 C under 5% CO2 . Cell line identities are
regularly confirmed by short tandem repeat profiling using the PowerPlex16 system
and GeneMapper software (Promega). Cell lines are regularly screened for the presence
of mycoplasma.
Cell viability assays in response to MEK inhibition.
For cell viability assays, 2.5-25 ⇥ 103 cells were seeded in 50 µl in 96-well plates
1 d before treatment with one of three MEK inhibitors. Binimetinib, trametinib or
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cobimetinib (Selleckchem) was added in a seven-point fivefold dilution series, and cell
viability was assayed by MTT assay (Sigma) after 72 h, as described previously[163].
All experiments were performed in triplicate, and values were compared to those for
solvent-treated controls. GI50 values were calculated by 100 ⇥ (T

T0 )/(C

T0 ) for

every drug concentration, where T is the optical density for a certain drug concentration
at 72 h, T0 is the optical density at 0 h (before adding the drug) and C is the optical
density of solvent-treated controls at 72 h. Curves were fitted on the data points
using nonlinear regression in GraphPad 5 (log(inhibitor) versus response - variable
slope), and GI50 values were interpolated from these curves. If curves did not reach
50% growth inhibition, the GI50 value was set at 10 µM.
Whole exome sequencing of neuroblastoma cell lines
Whole exome sequencing of the neuroblastoma cell lines SK-N-AS, NBL-S, Kelly
and IMR-5 was performed using in-solution hybrid capture[164] followed by Illumina sequencing, as described previously[46]. Cell lines were obtained from the Neuroblastoma
Cell Line Repository at the Children’s Hospital of Philadelphia.
MEK inhibition in murine xenotransplants
The human neuroblastoma-derived cell lines SK-N-AS, NBL-S, Kelly and IMR-5
were xenotransplanted subcutaneously into female C.B-17 SCID mice at 5-7 weeks
of age. Once the engrafted tumors reached 200 mm3 , mice were treated orally with
binimetinib (Novartis) at 3 mg/kg (n = 10) or 30 mg/kg (n = 10) or received vehicle
only (n = 10) by simple randomization. Mice were treated twice daily, and tumor size
was monitored three times weekly; all investigators other than the mouse technician
were blinded to group allocation and study outcomes until all mice completed a trial.
Tumor burden was determined according to the formula (⇡/6)d3 , where d represents
the mean tumor diameter obtained by caliper measurement. Statistical analysis was
performed using a two-tailed t-test at each time point, with P -values < 0.05 indicating
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significance between the vehicle-treated group and each of the treatment groups. All
studies were performed in accordance with the Children’s Hospital of Philadelphia
Institutional Animal Care and Use Committee, and mice were euthanized as soon as
tumor volume exceeded 3 cm3 . The sample size of ten mice was predetermined on the
basis of statistical power calculations.
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A. Engesser, Y. Kahlert, J. Theissen, B. Hero, F. Roels, J. Altmüller, P. Nürnberg,
K. Astrahantse↵, C. Gloeckner, K. De Preter, C. Plass, S. Lee, H. N. Lode,
K. O. Henrich, M. Gartlgruber, F. Speleman, P. Schmezer, F. Westermann,
S. Rahmann, M. Fischer, A. Eggert, and J. H. Schulte, “Mutational dynamics
between primary and relapse neuroblastomas.,” Nature genetics, vol. 47, no. 8,
pp. 872–877, 2015.
119

[126] D. D. Shao, W. Xue, E. B. Krall, A. Bhutkar, F. Piccioni, X. Wang, A. C.
Schinzel, S. Sood, J. Rosenbluh, J. W. Kim, Y. Zwang, T. M. Roberts, D. E.
Root, T. Jacks, and W. C. Hahn, “KRAS and YAP1 converge to regulate EMT
and tumor survival.,” Cell, vol. 158, no. 1, pp. 171–184, 2014.
[127] A. Kapoor, W. Yao, H. Ying, S. Hua, A. Liewen, Q. Wang, Y. Zhong, C. J. Wu,
A. Sadanandam, B. Hu, Q. Chang, G. C. Chu, A. Ramsey, S. Jiang, H. Xia,
F. Eliot, C. Lim, G. I. Horwitz, A. Viale, P. Pettazzoni, N. Sanchez, H. Wang,
A. Protopopov, J. Zhang, T. He↵ernan, R. L. Johnson, L. Chin, Y. Wang,
G. Draetta, and D. R. A, “Yap1 activation enables bypass of oncogenic kras
addiction in pancreatic cancer.,” Cell, vol. 158, no. 1, pp. 185–197, 2014.
[128] J. E. Yeh, P. A. Toniolo, and D. A. Frank, “Targeting transcription factors:
promising new strategies for cancer therapy,” Curr Opin Oncol, vol. 25, pp. 652–
658, Nov 2013.
[129] N. Krug, J. M. Hohlfeld, A. M. Kirsten, O. Kornmann, K. M. Beeh, D. Kappeler,
S. Korn, S. Ignatenko, W. Timmer, C. Rogon, J. Zeitvogel, N. Zhang, J. Bille,
U. Homburg, A. Turowska, C. Bachert, T. Werfel, R. Buhl, J. Renz, H. Garn,
and H. Renz, “Allergen-induced asthmatic responses modified by a GATA3specific DNAzyme.,” The New England journal of medicine, vol. 372, no. 21,
pp. 1987–1995, 2015.
[130] J. Chambers and T. H. Rabbitts, “Lmo2 at 25 years: a paradigm of chromosomal
translocation proteins,” Open biology, vol. 5, no. 6, p. 150062, 2015.
[131] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier,
“A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial
immunity.,” Science (New York, N.Y.), vol. 337, no. 6096, pp. 816–821, 2012.
120

[132] F. Ran, P. D. Hsu, C. Y. Lin, J. S. Gootenberg, S. Konermann, A. E. Trevino,
D. A. Scott, A. Inoue, S. Matoba, Y. Zhang, and F. Zhang, “Double nicking
by RNA-guided CRISPR cas9 for enhanced genome editing specificity.,” Cell,
vol. 154, no. 6, pp. 1380–1389, 2013.
[133] L. Cong, F. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu,
W. Jiang, L. A. Marraffini, and F. Zhang, “Multiplex genome engineering using
CRISPR/Cas systems.,” Science (New York, N.Y.), vol. 339, no. 6121, pp. 819–
823, 2013.
[134] T. J. Cradick, E. J. Fine, C. J. Antico, and G. Bao, “CRISPR/Cas9 systems
targeting -globin and CCR5 genes have substantial o↵-target activity.,” Nucleic
acids research, vol. 41, no. 20, pp. 9584–9592, 2013.
[135] I. B. Hilton, D. A. M, C. M. Vockley, P. I. Thakore, G. E. Crawford, T. E. Reddy,
and C. A. Gersbach, “Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.,” Nature biotechnology,
vol. 33, no. 5, pp. 510–517, 2015.
[136] N. A. Kearns, H. Pham, B. Tabak, R. M. Genga, N. J. Silverstein, M. Garber,
and R. Maehr, “Functional annotation of native enhancers with a cas9-histone
demethylase fusion.,” Nature methods, vol. 12, no. 5, pp. 401–403, 2015.
[137] H. Singh, D. L. Longo, and B. A. Chabner, “Improving prospects for targeting
RAS.,” Journal of clinical oncology : official journal of the American Society of
Clinical Oncology, vol. 33, no. 31, pp. 3650–3659, 2015.
[138] M. Puyol, A. Martı́n, P. Dubus, F. Mulero, P. Pizcueta, G. Khan, C. Guerra,
D. Santamarı́a, and M. Barbacid, “A synthetic lethal interaction between K-

121

Ras oncogenes and cdk4 unveils a therapeutic strategy for non-small cell lung
carcinoma.,” Cancer cell, vol. 18, no. 1, pp. 63–73, 2010.
[139] L. N. Kwong, J. C. Costello, H. Liu, S. Jiang, T. L. Helms, A. E. Langsdorf,
D. Jakubosky, G. Genovese, F. L. Muller, J. H. Jeong, R. P. Bender, G. C.
Chu, K. T. Flaherty, J. A. Wargo, J. J. Collins, and L. Chin, “Oncogenic NRAS
signaling di↵erentially regulates survival and proliferation in melanoma.,” Nature
medicine, vol. 18, no. 10, pp. 1503–1510, 2012.
[140] J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, and K. M. Shokat, “K-Ras(G12C)
inhibitors allosterically control GTP affinity and e↵ector interactions.,” Nature,
vol. 503, no. 7477, pp. 548–551, 2013.
[141] H. Thompson, “US national cancer institute’s new ras project targets an old
foe.,” Nature medicine, vol. 19, no. 8, pp. 949–950, 2013.
[142] N. E. Navin, “The first five years of single-cell cancer genomics and beyond.,”
Genome research, vol. 25, no. 10, pp. 1499–1507, 2015.
[143] V. Latorre, S. J. Diskin, M. A. Diamond, H. Zhang, H. Hakonarson, J. M. Maris,
and M. Devoto, “Replication of neuroblastoma SNP association at the BARD1
locus in African-Americans.,” Cancer epidemiology, biomarkers & prevention :
a publication of the American Association for Cancer Research, cosponsored by
the American Society of Preventive Oncology, vol. 21, no. 4, pp. 658–663, 2012.
[144] M. R. Mansour, B. J. Abraham, L. Anders, A. Berezovskaya, A. Gutierrez,
A. D. Durbin, J. Etchin, L. Lawton, S. E. Sallan, L. B. Silverman, M. L. Loh,
S. P. Hunger, T. Sanda, R. A. Young, and A. Look, “Oncogene regulation.
an oncogenic super-enhancer formed through somatic mutation of a noncoding

122

intergenic element.,” Science (New York, N.Y.), vol. 346, no. 6215, pp. 1373–1377,
2014.
[145] T. I. Lee, S. E. Johnstone, and R. A. Young, “Chromatin immunoprecipitation
and microarray-based analysis of protein location.,” Nature protocols, vol. 1,
no. 2, pp. 729–748, 2006.
[146] A. Marson, S. S. Levine, M. F. Cole, G. M. Frampton, T. Brambrink, S. Johnstone, M. G. Guenther, W. K. Johnston, M. Wernig, J. Newman, J. Calabrese,
L. M. Dennis, T. L. Volkert, S. Gupta, J. Love, N. Hannett, P. A. Sharp, D. P.
Bartel, R. Jaenisch, and R. A. Young, “Connecting microRNA genes to the
core transcriptional regulatory circuitry of embryonic stem cells.,” Cell, vol. 134,
no. 3, pp. 521–533, 2008.
[147] B. Langmead, C. Trapnell, M. Pop, and S. L. Salzberg, “Ultrafast and memoryefficient alignment of short DNA sequences to the human genome.,” Genome
biology, vol. 10, no. 3, p. R25, 2009.
[148] W. Kent, C. W. Sugnet, T. S. Furey, K. M. Roskin, T. H. Pringle, A. M. Zahler,
and D. Haussler, “The human genome browser at UCSC.,” Genome research,
vol. 12, no. 6, pp. 996–991006, 2002.
[149] Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein,
C. Nusbaum, R. M. Myers, M. Brown, W. Li, and X. Liu, “Model-based analysis
of ChIP-Seq (MACS).,” Genome biology, vol. 9, no. 9, p. R137, 2008.
[150] H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth,
G. Abecasis, R. Durbin, and . G. P. D. P. Subgroup, “The sequence Alignment/Map format and SAMtools.,” Bioinformatics (Oxford, England), vol. 25,
no. 16, pp. 2078–2079, 2009.
123

[151] J. Lovén, H. A. Hoke, C. Y. Lin, A. Lau, D. A. Orlando, C. R. Vakoc, J. E.
Bradner, T. I. Lee, and R. A. Young, “Selective inhibition of tumor oncogenes
by disruption of super-enhancers.,” Cell, vol. 153, no. 2, pp. 320–334, 2013.
[152] Y. Nakatani and V. Ogryzko, “Immunoaffinity purification of mammalian protein
complexes.,” Methods in enzymology, vol. 370, pp. 430–444, 2003.
[153] A. D. Durbin, G. R. Somers, M. Forrester, M. Pienkowska, G. E. Hannigan, and
D. Malkin, “JNK1 determines the oncogenic or tumor-suppressive activity of the
integrin-linked kinase in human rhabdomyosarcoma.,” The Journal of clinical
investigation, vol. 119, no. 6, pp. 1558–1570, 2009.
[154] R. Drmanac, A. B. Sparks, M. J. Callow, A. L. Halpern, N. L. Burns, B. G. Kermani, P. Carnevali, I. Nazarenko, G. B. Nilsen, G. Yeung, F. Dahl, A. Fernandez,
B. Staker, K. P. Pant, J. Baccash, A. P. Borcherding, A. Brownley, R. Cedeno,
L. Chen, D. Cherniko↵, A. Cheung, R. Chirita, B. Curson, J. C. Ebert, C. R.
Hacker, R. Hartlage, B. Hauser, S. Huang, Y. Jiang, V. Karpinchyk, M. Koenig,
C. Kong, T. Landers, C. Le, J. Liu, M. C. E, M. Morenzoni, R. E. Morey,
K. Mutch, H. Perazich, K. Perry, B. A. Peters, J. Peterson, C. L. Pethiyagoda,
K. Pothuraju, C. Richter, A. M. Rosenbaum, S. Roy, J. Shafto, U. Sharanhovich,
K. W. Shannon, C. G. Sheppy, M. Sun, J. V. Thakuria, A. Tran, D. Vu, A. W.
Zaranek, X. Wu, S. Drmanac, A. R. Oliphant, W. C. Banyai, B. Martin, D. G.
Ballinger, G. M. Church, and C. A. Reid, “Human genome sequencing using
unchained base reads on self-assembling DNA nanoarrays.,” Science (New York,
N.Y.), vol. 327, no. 5961, pp. 78–81, 2010.
[155] M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, S. J.

124

Jones, and M. A. Marra, “Circos: an information aesthetic for comparative
genomics.,” Genome research, vol. 19, no. 9, pp. 1639–1645, 2009.
[156] H. Li and R. Durbin, “Fast and accurate short read alignment with BurrowsWheeler transform.,” Bioinformatics (Oxford, England), vol. 25, no. 14, pp. 1754–
1760, 2009.
[157] M. Aaron, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky,
K. Garimella, D. Altshuler, S. Gabriel, M. Daly, and D. M. A, “The genome
analysis toolkit: a MapReduce framework for analyzing next-generation DNA
sequencing data.,” Genome research, vol. 20, no. 9, pp. 1297–1303, 2010.
[158] K. Cibulskis, M. S. Lawrence, S. L. Carter, A. Sivachenko, D. Ja↵e, C. Sougnez,
S. Gabriel, M. Meyerson, E. S. Lander, and G. Getz, “Sensitive detection of
somatic point mutations in impure and heterogeneous cancer samples.,” Nature
biotechnology, vol. 31, no. 3, pp. 213–219, 2013.
[159] K. Wang, M. Li, and H. Hakonarson, “ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data.,” Nucleic acids research,
vol. 38, no. 16, p. e164, 2010.
[160] . G. P. Consortium, G. R. Abecasis, A. Auton, L. D. Brooks, D. M. A, R. M.
Durbin, R. E. Handsaker, H. M. Kang, G. T. Marth, and M. G. A, “An integrated
map of genetic variation from 1,092 human genomes.,” Nature, vol. 491, no. 7422,
pp. 56–65, 2012.
[161] T. Rausch, T. Zichner, A. Schlattl, A. M. Stütz, V. Benes, and J. O. Korbel,
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